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The incidence and mortality of brain tumors have not changed over the last 3 decades and pose a 
significant burden on the healthcare system of the United States. Temozolomide (TMZ) is the 
preferred chemotherapeutic agent for the treatment of brain tumors and base excision repair 
(BER) is a major mechanism for the repair of TMZ-induced DNA base lesions. BER inhibition, 
either by interrupting the delicate balance of the expression of key BER proteins or by chemical 
inhibitors, enhances cytotoxicity of chemotherapeutic DNA damaging agents such as TMZ. 
Understanding the mechanisms of enhanced cytotoxicity brought on by BER inhibition has great 
public health significance. 
By using DNA polymerase ß (Polß) deficiency as a model of BER inhibition, I report that 
DNA damage-induced cytotoxicity due to Polß deficiency triggers cell death dependent on 
PARP activation yet independent of poly(ADP-ribose) (PAR) or PAR-catabolite signaling. Cell 
death is rescued by the NAD
+
 metabolite NMN and is synergistic with inhibition of NAD
+
 
biosynthesis demonstrating that DNA damage-induced cytotoxicity mediated via BER inhibition 
is primarily dependent on cellular metabolite bioavailability. I offer a mechanistic justification 
for the elevated alkylation-induced cytotoxicity of Polß deficient cells, suggesting a linkage 
between DNA repair, cell survival and cellular bioenergetics. 
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Resistance to TMZ is partially attributed to efficient repair of TMZ-induced DNA 
lesions. Using the human glioma cell lines LN428 and T98G, I report here that potentiation of 
TMZ via BER inhibition (methoxyamine (MX), the PARP inhibitors PJ34 and ABT-888 or 
depletion (knockdown) of PARG) is greatly enhanced by increasing BER initiation via over-
expression of MPG. I also show that MX-induced potentiation of TMZ in MPG expressing 
glioma cells is abrogated by elevated-expression of the rate-limiting BER enzyme Polß, 
suggesting that cells proficient for BER readily repair AP sites even in the presence of MX. This 
study demonstrates that increased initiation of BER via MPG over-expression, together with 
inhibition of repair following initiation, further sensitizes glioma cells to alkylating agent TMZ, 
suggesting that the expression level of MPG might be used to predict the effectiveness of BER 
inhibition-induced potentiation of TMZ in glioma cells. 
 vi 
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1.0  STATEMENT OF THE PROBLEM 
Efficacy of chemotherapy or radiation treatment is intimately dependent on DNA repair capacity. 
Base excision repair (BER) is one of the major mechanisms conferring resistance to DNA 
damage-induced cytotoxicity. The mechanism of enhanced cytotoxicity of chemotherapeutic 
DNA-damaging agents via BER inhibition and the methodologies to improve chemotherapy 
efficacy are of great importance from both public health and clinical perspectives.  
The BER pathway repairs DNA base lesions through the assembly and coordinated 
function of a series of repair complexes at the site of the DNA lesion. The expression of BER 
proteins is under cellular regulation to ensure coordinated function of the components of the 
repair complexes. An imbalance of BER protein expression, for example DNA polymerase ß 
(Polß) deficiency, is a form of BER inhibition that enhances cytotoxicity of radiation and 
chemotherapeutic DNA-damaging agents. Despite recent progress that has been made to 
elucidate the mechanism of BER inhibition-induced sensitization, the signaling pathways and 
cell death mediators that lead to increased cytotoxicity remain unknown. 
Temozolomide (TMZ) is the preferred chemotherapeutic alkylating agent in the treatment 
of glioma following surgical resection and/or radiation. One mechanism of resistance to TMZ is 
attributed to efficient repair of TMZ-induced DNA lesions by the BER pathway. It has been 
shown that increased repair initiation of the BER pathway provides enhanced cytotoxicity of 
cancer cells to TMZ. However, it is not clear if increased repair initiation can be combined with 
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inhibition of repair steps following repair initiation to achieve further sensitization of cancer 
cells. 
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2.0  SPECIFIC AIMS 
Specific Aim 1: To determine if poly(ADP-ribose) polymerase 1 (PARP1) mediates cell 
death in response to BER inhibition. In the absence of the BER rate-limiting enzyme Polß, 
cellular hypersensitivity to alkylating agents have been observed in mouse embryonic fibroblasts 
(MEFs), in human cancer cells and in animal models. Although the cellular hypersensitivity is 
known to be due to the accumulation of BER intermediates resulting from incomplete repair, the 
exact downstream signaling process leading to cell death is unclear. I propose that PARP1 
functions in BER as a molecular sensor, signaling in response to the inhibition of BER and 
leading to cellular energy depletion-dependent cell death. To address this hypothesis the 
following experiments are proposed: A) Correlate enzymatic activation of PARP1 with 
inhibition of the BER pathway. B) Determine the functional significance of PARP1 activation in 
controlling short-term survival of cells following BER inhibition. C) Determine the specific cell 
death mechanisms that are activated following PARP1 activation. 
 
Specific Aim 2: To test the hypothesis that increased repair initiation enhances BER 
inhibition-mediated sensitization of glioma cells to TMZ. Increased repair initiation via over-
expression of the BER initiating enzyme N-methylpurine DNA glycosylase (MPG) has been 
reported to sensitize human breast cancer cells, osteosarcoma cells, and ovarian cancer cells to 
TMZ. Enhanced sensitivity to alkylating agents have also been observed by inhibition of the 
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BER pathway in preclinical studies, suggesting BER modulation is an attractive strategy for 
chemotherapy potentiation. I propose that BER inhibition-induced sensitization is dependent 
on BER initiation and increased repair initiation can be combined with BER inhibition to 
further increase efficacy of alkylation treatment. To address this hypothesis, I propose the 
following experiments. A) Determine if methoxyamine (MX)-induced sensitization of glioma 
cells to TMZ can be enhanced by increased initiation of BER. B) Assay if depletion of PARG 
and the resulting potentiation of TMZ can be increased by elevated repair initiation. C) Assess if 
inhibition of PARP-induced sensitization of TMZ can be enhanced by increased repair initiation.  
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3.0  INTRODUCTION 
3.1 GLIOMA AND CHEMOTHERPAY 
3.1.1 Brain tumors and glioma 
Neoplastic transformation in the central nervous system (CNS) is a multistep process involving 
cellular and genetic alterations and the interaction between those alterations and environmental 
factors (1). Primary benign and malignant brain tumors are common. It is the second most 
common cancer and the most common solid tumor in childhood (1). The incidence of primary 
brain and CNS tumors has remained at a similar level over the last 3 decades (2). The overall 
incidence rate for 2004-2005 was 18.16 per 100,000 person-years. The overall incidence rate was 
4.58 per 100,000 person-years for children 0-19 years of age and 23.62 per 100,000 person-years 
for adults (20+ years) (2). Glial tumors, primitive neuroectodermal tumors (PNETs), 
meningiomas, and schwannomas represent the most common types of brain tumors. Among 
them, gliomas account for approximately 40-45% of all intracranial tumors and thus are the most 
common primary brain tumors. Depending on the specific type of cells, gliomas are classified 
into several subgroups, the most frequent being astrocytomas (accounts for 75% of all gliomas), 
oligodendroglial tumors, mixed gliomas (oligoastrocytomas), and ependymal tumors (3). 
Astrocytomas may be divided into two major groups. One group is more commonly seen with 
diffusely infiltrating properties. It includes astrocytoma, anaplastic astrocytoma, and 
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glioblastoma. The other group is less common with more circumscribed growth, comprising 
pilocytic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell 
astrocytoma of tuberous sclerosis (3). Depending on histopathology, astrocytomas are divided 
into three grades of malignancy: World Health Organization (WHO) grade II diffuse 
astrocytoma, WHO grade III anaplastic astrocytoma, and WHO grade IV glioblastoma (4). The 
prognosis of brain tumors is among the worst of all tumors. Although patients with grade II or 
grade III astrocytomas may survive for 5 or 2-3 years respectively, most of grade IV 
glioblastoma patients survive substantially less than 2 years (1). 
Genetic alterations play a key role in the development of astrocytomas. Inactivation of 
p53, a tumor suppressor encoded by the TP53 gene, plays an important role in the development 
of at least one third of all adult astrocytoma (5, 6). The PTEN tumor suppressor gene at 10q23.3 
is often deleted in astrocytoma, as loss of chromosome 10 is found to occur in 60% to 95% of 
glioblastoma multiforme (GBM) and to a lesser extent in anaplastic astrocytoma (7). Epidermal 
growth factor receptor (EGFR) is consistently reported to be amplified in approximately 40% of 
all GBM, resulting in over-expression of EGFR transcript and protein (8). Other genetic 
alterations include chromosomal losses mapping to 9p and 13q, all of which targets a critical cell 
cycle regulatory complex consisting of p16, cyclin-dependent kinase 4 (cdk4), cdk6, cyclin D1, 
and retinoblastoma (Rb) proteins. P16 controls cells from entering S phase by inhibiting the 
cdk4/cyclin D1 and/or cdk6/cyclin D1 complexes, preventing them from phosphorylating Rb, 
and so maintaining cells in the G1 phase of the cell cycle. The loss of chromosome 9p targets the 
CDKN2A locus, which encodes p16 protein, and the loss of 13q preferentially inactivates Rb 
function. They occur in approximately 50% (9p) or 30%-50% (13q) of high-grade astrocytomas 
(1). 
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3.1.2 Temozolomide and glioma chemotherapy 
The standard treatments for glioma are surgery, radiation therapy and chemotherapy. Radiation 
therapy and/or chemotherapy are generally used as secondary or adjuvant treatments following 
surgery. However, radiation and chemotherapy may be used without surgery if the tumor is 
inoperable. Therapeutic alkylating agents, the mainstay of glioma chemotherapy, damage DNA 
by transferring alkyl-adducts to DNA bases. They include TMZ, nitrosourea-based alkylating 
agents, carmustine (bichloroethyl nitrosourea, or BCNU) and lomustine (chloroethylnitrosourea, 
or CCNU), streptozotocin, procarbazine and dacarbazine. Although BCNU and CCNU showed a 
modest effect as adjuvant therapy for GBM, their use has been supplanted by TMZ and the latter 
became the preferred and widely used alkylating agent in the treatment of glioma (9). In a 
landmark international trial, Stupp et al. reported that patients receiving radiotherapy plus 
concurrent TMZ followed by six cycles of adjuvant TMZ had significantly increased median and 
2-year survival compared to those receiving radiotherapy alone after surgery (10). In a 
randomized phase II trial, TMZ also showed benefits over procarbazine in patients with recurrent 
glioblastoma, in terms of progression free survival and health-related quality-of-life (11). TMZ 
induces tumor cell cytotoxicity by adding a methyl group to DNA bases. There are three major 
types of base modifications. The major site of methylation is the N7 position of guanine (>70%) 
followed by the N3 position of adenine (9.2%) and the O
6
 atom of guanine (5%) (12) (Table 
1.1). The N7 atom of guanine has the highest negative electrostatic potential of all the other 
atoms within DNA bases, which makes it the most vulnerable site to electrophilic attack by 
alkylators and N7-methylguanine (7MeG) constitutes the majority of TMZ-induced base lesions. 
7MeG by itself does not possess any significant mutagenic or cytotoxic effects. However, over- 
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Table 1.1 TMZ-induced base lesions 
Chemical structures and corresponding 
frequencies of TMZ-induced DNA base 
lesions. 
 
70% 
 
9.2% 
  
5% 
expression of MPG, the mammalian repair enzyme that removes 7MeG lesions, sensitizes human 
breast cancer cells to TMZ by converting 7MeG into toxic repair intermediates (13, 14). While 
N3-methyladenine (3MeA) does not have major mutagenic effects, the cytotoxicity of 3MeA is 
well established in the literature (15). The cytotoxic effect of 3MeA derives from its ability to 
block replication and its potential to give rise to toxic repair intermediates following removal by 
MPG (16). If left un-repaired, O
6
-methylgaune (O
6
MeG) pairs with thymine during DNA 
replication and causes GA transition mutations. It is the primary mutagenic lesion induced by 
most alkylation damage to the genome (17). The cytotoxicity of O
6
MeG seems to be the primary 
contributor of cytotoxicity induced by TMZ. The mechanism has been shown to be related to 
abortive mismatch repair (MMR) (15). Two models have been proposed to explain the 
cytotoxicity induced by this lesion. The first suggests that MMR acts as a sensor of the O
6
MeG:T 
 9 
mispair and directly activates apoptotic signaling that involves ATR/ATRIP (18, 19). The second 
model proposes that cytotoxicity is due to futile cycling of the mismatch repair system at an 
O
6
MeG:T base pair. The model proposes that, upon recognition of the O
6
MeG:T mispair, MMR 
removes the newly incorporated thymine from the nascent strand. During repair synthesis, 
thymine is once again incorporated opposite the O
6
MeG lesion, resulting in initiation of another 
round of repair by the MMR system. This recursive cycling of excision and synthesis is thought 
to produce DNA strand breaks that activate DNA damage signaling pathways, leading to 
cytotoxicity (20). 
3.2 CHEMOTHERAPY RESISTANCE AND DNA REAPIR 
3.2.1 Glioma chemotherapy resistance 
Chemotherapy resistance of malignant glioma results from two major avenues, innate and 
acquired resistance, and resistance to alkylating agents is the major cause of treatment failure in 
patients with malignant brain tumors (21). Acquired resistance is normally related to the 
difficulties of delivering chemotherapeutics to tumor cells and reaching a homogenous cytotoxic 
concentration. Exposure of tumor cells to sub-lethal concentrations of drug increases the chances 
of acquired resistance (1). Despite the ability of TMZ to readily cross the blood brain barrier and 
to achieve an effective therapeutic concentration in the brain, the innate resistance of tumor cells 
remains the greatest obstacle to the successful treatment of glioma. Innate resistance is a result of 
specific cellular and genetic properties of tumor cells that efficiently repair and/or tolerate 
damage caused by chemotherapeutics. Deleterious genetic alterations in gliomas, for instance 
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loss of p53 or PTEN, confer tumor cells the ability to circumvent cell cycle arrest and apoptosis 
and provide a mechanism of DNA damage tolerance. Primary GBM are resistant to apoptosis 
due to universal over-expression of BCL2L12, which blocks the activation of both caspase-3 and 
caspase-7 (22, 23). TMZ mainly induces three types of DNA base lesions, all of which are 
readily repaired by defensive repair mechanisms in cells, because those lesions are also 
continuously produced by endogenous insults present in cells (15). Two mechanisms are 
responsible for the repair of TMZ-induced base lesions. The 7MeG and 3MeA lesions are 
primarily repaired by the BER pathway and inhibition of the BER pathway through genetic 
means or via chemical inhibitors results in enhanced cytotoxicity of alkylating agents (24). The 
O
6
MeG lesion is repaired by O
6
-methylguanine-DNA methyltransferase (MGMT). MGMT 
conducts repair of the O
6
MeG lesion through a suicide mechanism, which covalently transfers 
the methyl group on the O
6
 atom of guanine to the conserved active-site cysteine of MGMT, 
restoring the guanine to normal and inactivating the MGMT protein (25). Although a proportion 
of gliomas have been found to lack the expression of MGMT due to hyper-methylation of the 
MGMT promoter and thus have diminished DNA repair activity, at least half of GBM express 
MGMT and the expression is associated with resistance to chemotherapy and poor prognosis 
(26). Therefore, it is important to either overcome resistance rendered by expression of MGMT 
or find an alternative that improves efficacy of chemotherapy in the presence of MGMT activity. 
In this study, I show how modulation of the BER pathway provides enhanced sensitization of 
glioma cells to TMZ and a detailed mechanism of the increased sensitization is demonstrated. 
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3.2.2 Base excision repair 
BER is the predominant DNA damage repair mechanism for the repair of base lesions (Figure 
1.1). It not only protects normal cells from endogenous DNA damage derived from oxidation and 
alkylation, but also provides cancer cells with resistance to chemotherapy treatment. Under  
 
Figure 1.1 The BER pathway 
Simplified model of the short-patch 
base excision repair pathway. 
normal physiologic conditions, a functional BER pathway is essential to maintain genomic 
integrity as it has been estimated that 10
4
 DNA bases are damaged per mammalian cell per day 
(27-29). The repair process is initiated with removal of damaged bases by a lesion-specific DNA 
glycosylase and completed by either a short-patch or long-patch BER mechanism. Following 
cleavage of the phosphodiester backbone immediately 5‟ to the abasic site (AP site) by 
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apurinic/apyrimidinic endonuclease 1 (APE1), via the so called short-patch BER pathway, Polß 
hydrolyzes the resulting 5‟deoxyribose phosphate (5‟dRP) moiety and inserts a single nucleotide. 
Alternatively, in the long-patch repair pathway, an overhang of 2 to 12 bases is produced by 
DNA polymerases (polymerase δ, ε, or ß) as a result of repair synthesis and strand displacement 
and the DNA overhang is excised by Flap endonuclease 1 (FEN1). It is currently thought that the 
majority of repair is carried out via the short-patch pathway (30). Following DNA strand 
incision, repair synthesis, and end tailoring if necessary, DNA Ligase I (LIGI) or a complex of 
DNA Ligase IIIα (LIGIIIα) and X-ray repair cross complementing protein 1 (XRCC1) complete 
the repair by sealing the nick in DNA (31).  
 
3.2.3 Poly(ADP-ribosyl)ation and base excision repair 
Poly(ADP-ribosyl)ation is a form of post translational modification of proteins that is mediated 
by poly(ADP-ribose) polymerases (PARP). PARP1 is the founding member of a large family of 
poly(ADP-ribose) polymerases with 17 members identified (32, 33). It is an abundant nuclear 
enzyme found in many eukaryotes, with the exception of yeast. It plays a primary role in the 
process of poly(ADP-ribosyl)ation, a post-translational modification that regulates a variety of 
cellular functions, including DNA repair, chromatin structure and transcription (32, 33). This 
highly conserved 113-kDa enzyme consists of three domains (34): an N-terminal 42-kDa DNA-
binding domain, a 16-kDa automodification domain, and a 55-kDa C-terminal catalytic domain 
(Figure 1.2).  
The enzyme can be activated by a large spectrum of DNA damaging agents that directly 
or indirectly introduce DNA strand interruptions, including alkylating agents, reactive oxygen  
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Figure 1.2 Schematic of the structure of human PARP1. 
Three zinc fingers are present in the N-terminal DBD domain. They are 
responsible for DNA-binding, PARP1 enzymatic activity activation, 
and some protein-protein interactions. NLS, nuclear localization signal. 
species, and ionizing radiation (33). The activated enzyme catalyzes the transfer of ADP-ribose 
units from donor NAD
+
 molecules to many nuclear target proteins, including itself, as it is the 
primary acceptor of the modification (33). PARP1 has been suggested to play a role in necrosis. 
Previous research indicates that the PARP1-mediated ADP-ribosylation modification may alter 
the activity, function and cellular location of several cell death related factors. For example, it 
has been reported that PARP1 activation mediates translocation of apoptosis inducing factor 
(AIF) from the mitochondria to the nucleus, which results in large-scale DNA fragmentation and 
eventually cell death (35). Moreover, hyper-activation of PARP1, as a result of a high level of 
DNA damage, can lead to a rapid decrease in cellular NAD
+
 levels and subsequent energy failure 
associated necrotic cell death (36, 37). 
PARP1 was first suggested to play a role in BER by in vitro experimental evidence 
suggesting that PARP1 facilitates the repair of single-stranded DNA breaks (SSBs) in the 
presence of NAD
+
 (38). Later, PARP1 KO mice and cells derived from those mice have been 
shown to be more sensitive to alkylation, radiation, and oxidative DNA damage compared to its 
wild type (WT) counterparts (39, 40), suggesting that PARP1 participates and contributes to the 
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repair of DNA base lesions. Physical interactions of PARP1 and BER proteins, including 
XRCC1 (41), Polß (39, 42), and LIGIIIα (43), and the functional interplay between PARP1 and 
XRCC1 (44) establish a role for PARP1 in BER. 
 
3.2.4 Mechanism of base excision repair inhibition induced cytotoxicity 
Efficacy of chemotherapy or radiation treatment is intimately dependent on DNA repair capacity 
(21). Robust repair of therapeutically induced DNA damage can provide significant resistance 
whereas tumor-specific defects in DNA repair or inhibition of specific DNA repair proteins can 
provide therapeutic advantage (45). In particular, inhibiting BER can be an effective means to 
improve response to TMZ, radiation, bleomycin and cisplatin, among other treatments (24, 46-
52). Like most DNA repair pathways, BER is a multi-step mechanism comprised of greater than 
20 proteins, depending on the initial base lesion (53). However, inhibiting each step in the BER 
pathway will have different outcomes. DNA glycosylase inhibition or loss blocks BER initiation, 
leading to the accumulation of both cytotoxic (54) and mutagenic base lesions (55), with the 
latter contributing to cellular dysfunction. In this regard, the preferred option is the inhibition of 
BER after repair initiation, promoting the accumulation of cytotoxic BER intermediates such as 
AP sites and SSBs by inhibiting AP site repair with MX, inhibiting the BER enzyme PARP1 or 
by loss or inhibition of Polß (45, 56, 57). We refer to inhibition of the intermediate steps in BER 
as the induction of “BER failure”, since repair is initiated yet is unable to be completed. 
Importantly, understanding the mechanisms that are responsible for the increase in cell 
death due to BER inhibition or BER failure is critical in tailoring treatment, as well as, designing 
rational adjuvant or combination treatments that may further increase overall response. For 
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example, inhibiting PARP1 has been shown to be effective in improving TMZ induced cell death 
(58). Inhibition of PARP1 results in the accumulation of replication-mediated DNA double-
stranded breaks (DSBs) and the onset of apoptosis (59, 60). This detailed understanding of the 
mechanism of cell death induced by combining a DNA damaging agent (TMZ) and a PARP1 
inhibitor suggests that PARP1 inhibition would be effective against many tumors but may be 
ineffective against tumors that are resistant to apoptosis (22). Further, cell death induced by 
PARP1 inhibition suggested a requirement for homologous recombination (HR) in the cellular 
response to the accumulated DSBs, prompting pre-clinical and clinical trials of PARP1 inhibitors 
in the treatment of HR defective tumors (45).  
There are several BER proteins essential for the repair of TMZ-induced DNA lesions. 
Using a MEF cell model, we have shown that loss of Polß can significantly improve the 
cytotoxic effect of TMZ (51), suggesting that inhibition of Polß may improve response to TMZ 
in human tumor cells. TMZ is currently used in the treatment of glioblastoma (61) and it is 
therefore critical to evaluate the role of Polß in glioma cell response to TMZ treatment. No 
previous studies have investigated the role of Polß in the response of human glioma tumor cells 
to TMZ. Further, there is no mechanistic explanation for the increase in alkylation-induced cell 
death observed in cells that are deficient in Polß beyond the evidence that cell death in mouse 
cells is the result of accumulation of un-repaired BER intermediates (51, 57). 
Acute alkylation damage has been suggested to induce cell death by multiple 
mechanisms, including necrosis (62), caspase-3 and caspase-9 activation and the onset of 
apoptosis (63), AIF translocation from the mitochondria to the nucleus (35, 64, 65), ADP-ribose 
induced activation of the Ca
2+
 channel TRPM2 or AMP-mediated inhibition of ATP transport 
(66-68).  In most, if not all cases, cell death has been attributed to the direct action of either PAR 
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formed by PARP1 activation or PAR catabolites that accumulate after PAR degradation by the 
catabolic enzyme poly(ADP-ribose) glycohydrolase (PARG). Polß deficient mouse cells are 
hypersensitive to the cell killing effects of alkylating agents due to failure to repair the 5‟dRP 
BER intermediate (69). However, the exact downstream signaling events and mechanism of 
cytotoxicity specifically induced by the un-repaired 5‟dRP lesion remains unclear. Previous 
studies in mouse cells have not been conclusive. One report suggested that the absence of Polß 
led to damage-induced cell death via apoptosis (70) whereas a later study proposed a necrotic 
form of cell death for both wild-type and Polß deficient cells (71), similar to what has been 
proposed as a general mechanism of alkylation-induced cell death in mouse fibroblasts (62). 
However, this latter study required the use of apoptosis-deficient cells to observe necrotic cell 
death (62). None of these previous studies have identified a mechanism of cell death specific to 
Polß deficiency and BER failure or a failure to repair the cytotoxic BER intermediate 5‟dRP. 
The studies described herein were designed to specifically define the mechanism of cell 
death in human tumor cells resulting from failure to repair the BER intermediate 5‟dRP due to 
„inhibition of‟ or a „deficiency in‟ Polß (BER failure). I have hypothesized that PARP1 
functions in BER as both a complex coordinator and as a molecular repair sensor. As a BER 
molecular sensor, I suggest that PARP1 facilitates cell death in response to incomplete BER or 
BER failure. In support of this hypothesis, I show that a specific BER intermediate, a single-
strand DNA strand break containing a 3‟OH and 5‟dRP, is an in vivo substrate in human cells 
that activates PARP1 in the context of BER and that elevated cytotoxicity observed in Polß 
deficient human cells is controlled by the activation of PARP1. Further, I provide clear evidence 
that following “BER failure”, human cells die independent of receptor-interacting protein 1 
(RIP1) activation or AIF translocation, thus ruling out PAR as the cell death signal that is 
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initiated upon BER failure. Further, I show that the observed cell death in Polß deficient cells is 
un-related to the accumulation of PAR catabolites such as ADP-ribose or AMP yet is dependent 
on NAD
+
 metabolite bioavailability or the bioenergetic capacity of the cell. 
This study provides mechanistic insight into why Polß deficiency leads to cell death, 
defines the mode of death and offers a mechanistic link between BER failure and energy 
metabolism - the novel finding that DNA damage-induced cytotoxicity mediated via BER 
inhibition is primarily dependent on cellular metabolite bioavailability. Finally, I offer a 
mechanistic justification for the elevated alkylation-induced cytotoxicity of Polß deficient cells, 
suggesting a linkage between DNA repair, cell survival and cellular bioenergetics. 
 
3.2.5 Modulation of base excision repair in chemotherapy sensitization 
TMZ is an oral chemotherapeutic agent approved for the treatment of anaplastic astrocytoma and 
newly diagnosed glioblastoma (72). It also showed clinical activity in metastatic melanoma and 
is under clinical evaluation for use in other cancers, including leukemia, lymphoma, 
aerodigestive tract, pancreatic and neuroendocrine tumors as well as cancers that have 
metastasized to the brain (73). TMZ causes cancer cell cytotoxicity by methylating genomic 
DNA, producing cytotoxic and/or mutagenic abnormal DNA bases (74). However, the ability of 
cancer cells to recognize and repair those DNA lesions confers chemotherapeutic resistance and 
limits therapeutic efficacy (21). The majority of TMZ-induced DNA lesions, including 7MeG 
and 3MeA, are repaired by the BER pathway (74), while the O
6
MeG is directly removed by 
MGMT (75, 76). Although O
6
MeG constitutes only a small proportion of the base lesions 
produced by TMZ, it is the most cytotoxic lesion and constitutes a significant level of TMZ-
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induced cytotoxicity (73). Since O
6
MeG-induced cytotoxicity is mediated through the MMR 
pathway, sensitivity to TMZ requires both low MGMT repair activity and functional MMR (73). 
At least half of glioblastoma multiforme (GBM) express MGMT and the expression is associated 
with resistance to chemotherapy and poor prognosis (26). Loss of the MMR protein MSH6, due 
to somatic mutations, has also been shown to be associated with glioblastoma recurrence post 
radiation and TMZ treatment (77). Therefore, it is important to either overcome resistance 
resulting from MGMT activity or find an alternative that improves efficacy of TMZ in the 
presence of MGMT activity. However, MGMT inhibitors (e.g., Patrin) have not shown clinical 
efficacy (73, 78). Pharmacological inhibition of the BER pathway, which repairs the 7MeG and 
3MeA lesions induced by TMZ, has been shown to enhance TMZ-induced cytotoxicity 
independent of MGMT status (79). 
The repair of TMZ-induced base damage by the BER pathway starts with the recognition 
and removal of the damaged bases by MPG, also known as alkyladenine DNA glycosylase 
(AAG) (76). The AP site produced following the action of MPG is then hydrolyzed by APE1 
resulting in the incision of the damaged DNA strand and formation of a 3‟OH group and a 5‟dRP 
group in the repair gap (53). PARP1 together with poly(ADP-ribose) polymerase 2 (PARP2) and 
PARG recognizes the DNA strand interruption and facilitates the recruitment of subsequent BER 
proteins, including the BER scaffold protein XRCC1 and Polß (53). Polß subsequently 
hydrolyzes the 5‟dRP moiety and inserts a single nucleotide, preparing the strand for ligation by 
a complex of DNA Ligase IIIα and XRCC1 to complete the repair process (69). 
Enhanced sensitivity to alkylating agents has been observed by modulating the BER 
pathway in preclinical studies, suggesting BER modulation is an attractive option for 
chemotherapy potentiation (80). Currently, several BER proteins are under active investigation 
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as potential targets for chemotherapy sensitization, including APE1 (56), PARP1 (81), PARG 
(82) and Polß (51, 52, 83-85). MX is a small molecule that specifically inhibits BER (86). It is 
currently under a phase I clinical trial under the name of TRC102 (ClinicalTrials.gov Identifier: 
NCT00692159). MX inhibits repair of AP sites by binding and modifying the AP sites, rather 
than directly inhibiting the enzyme APE1. An AP site modified by MX is refractory to APE1, 
preventing it from processing by the ensuing steps of BER and is eventually cytotoxic (50). MX 
potentiates a wide range of DNA damaging agents that produce AP sites regardless of the status 
of MMR, MGMT, and p53 (56). 
PARP1 is the primary enzyme in human cells that catalyzes the transfer of ADP-ribose 
units from NAD
+
 to target proteins, including itself. Under normal physiologic conditions, 
PARP1 facilitates the repair of DNA base lesions by helping recruit BER proteins XRCC1 and 
Polß (87). Inhibition of PARP1 results in decreased repair of DNA base damage and increased 
sensitivity of cells to alkylating agents, which makes it an attractive and effective target for 
chemotherapy sensitization (88). Many PARP inhibitors have been developed and tested in 
several tumor types (89). They have been shown to enhance the cytotoxicity of TMZ against 
glioma (90-92), leukemia (93), lung (94, 95) and colon (95-97) carcinoma. It has been shown 
recently that a PARP inhibitor (ABT-888) + TMZ therapy has broad activity in multiple 
histologic types in subcutaneous and challenging orthotopic or metastatic models (98). PARG is 
the main enzyme responsible for degradation of PAR in vivo via endo- and exo-glycosidic 
cleavage. Although complete ablation of PARG activity leads to early embryonic lethality, 
embryonic stem cells derived from PARG null mouse (99) and cells from PARG110 (one of three 
isoforms of PARG) deficient mice (100) have been shown to be sensitive to alkylating agents 
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and ionizing radiation. It has also been shown that inhibition of PARG activity sensitized 
malignant melanoma to TMZ in mouse models (82). 
Over-expression of MPG has been reported to sensitize human breast cancer cells (52, 
101), osteosarcoma cells (102), and ovarian cancer cells (49) to the chemotherapeutic agent 
TMZ. The increased sensitivity has been shown to be the result of increased repair initiation of 
the non-toxic 7MeG lesion (13), saturating the enzymatic activity of Polß resulting in 
accumulation of cytotoxic 5’dRP repair intermediates (51). Since BER inhibitors (e.g., AP site 
repair inhibition by MX, PARP or PARG inhibition) inhibit the repair steps following BER 
initiation, I hypothesized that MPG over-expression might further increase BER inhibitor-
induced sensitization of glioma cells to the alkylating agent TMZ. In this study, I show that over-
expression of MPG sensitizes glioma cells (LN428 and T98G) to MX, the PARP inhibitors PJ34 
and ABT-888, or PARG inhibition (knockdown) following exposure to TMZ, suggesting that 
increased initiation of BER combined with inhibition of the ensuing repair steps provides 
enhanced sensitization of glioma cells to TMZ.  
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4.0  MATERIALS AND METHODS 
4.1 MATERIALS 
4.1.1 Chemicals and reagents 
Alpha EMEM was from Mediatech. RPMI 1640 and DMEM were from Cambrex Bioscience 
Group and Biowhittaker, respectively. Fetal bovine serum (FBS), heat inactivated FBS, 
Pen/Strep/Ampho, glutamine and antibiotic/antimycotic were from InVitrogen. TMZ was 
obtained from the National Cancer Institute Developmental Therapeutics Program. A TMZ stock 
solution was prepared in dimethyl sulfoxide (DMSO) at 100 mM. Methyl methanesulfonate 
(MMS) was from Sigma-Aldrich. N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG) was obtained 
from TCI America, dissolved in DMSO to a stock concentration of 10 mM, filtered through a 
0.22 m filter and stored at -20°C before use. Puromycin, Gentamicin and Neomycin were 
purchased from Clontech Laboratories, Irvine Scientific and InVitrogen, respectively. PJ34 and 
Z-VAD.fmk were purchased from Calbiochem. MX, Necrostatin-1, and 3-methyladenine (3-
MA) were purchased from Sigma. BAPTA.AM was from InVitrogen. ß-nicotinamide 
mononucleotide (NMN) was from Sigma and Nicotinic Acid (NA) was obtained from Fisher. 
ABT-888 was kindly provided by Abbott Laboratories. 
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4.1.2 Plasmids, RNAi vectors and lentivirus preparation 
Human MPG (WT) was expressed using the plasmid pRS1422, as described previously (52). The 
MPG expression plasmid (pRS1422) was then mutated at residue N169 using the Quickchange 
XL Site-Directed Mutagenesis Kit (Stratagene) to yield pIRES-Neo-MPG-N169D. The 
expression plasmid for FLAG-tagged WT human Polß was generated by PCR amplification of 
the human Polß cDNA using a FLAG-containing forward oligonucleotide and cloned into 
pENTR/D-TOPO as we described previously (52). pENTER/Flag-Polß(WT) was then mutated at 
residue K72 as described above to yield pENTER/Flag-Polß (K72A). Flag-Polß (WT) and Flag-
Polß (K72A) was subsequently cloned into a Gateway-modifed pIRES-Puro vector by TOPO 
cloning, as we have described previously (52). The FIV-based lentiviral shRNA expression 
vector system specific for human Polß was as described previously (52) but was modified for 
copGFP expression (pSIF-H1-hPOLB1-copGFP). FIV-based lentiviral particles were generated 
by co-transfection of plasmid pCDF1-MCS1-EF1-copGFP (control) or pSIF-H1-hPOLB1-
copGFP (Polß shRNA) together with pFIV-34N and pVSV-G into 293-FT cells (103) using 
FuGene 6 Transfection Reagent (Roche). HIV-based lentiviral particles for co-expression of 
PARG shRNA and TurboGFP was prepared by transfection of four plasmids (the control 
plasmid pLK0.1-Puro-tGFP or the human PARG-specific shRNA plasmid pLK0.1-Puro-
PARGshRNA4, plus pMD2.g(VSVG), pRSV-REV and pMDLg/pRRE) into 293-FT cells (104, 
105) using FuGene 6 transfection reagent (Roche Diagnostic Corp, Indianapolis, IN). Culture 
media from transfected cells was collected 48 hours after transfection to isolate the viral 
particles, passed through 0.45 µm filters, used immediately or stored at -80°C in single-use 
aliquots. 
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4.2 METHODS 
4.2.1 Cell culture and cell line development 
The cell line LN428 is an established glioblastoma-derived cell line with mutations in TP53, 
deletions in p14
ARF
 and p16 and is WT for PTEN (106, 107). LN428 cells were kindly provided 
by Ian Pollack (University of Pittsburgh) and were cultured in Alpha EMEM supplemented with 
10% heat inactivated FBS, glutamine, antibiotic/antimycotic and Gentamycin. MDA-MB-231 
cells and derivatives were described previously (52). Human MPG (WT), human MPG (N169D), 
Flag Polß (WT) and Flag Polß (K72A) expressing cell lines were developed by transfection 
using FuGene 6 Transfection Reagent (Roche) according to the manufacturer‟s protocol. 
Transfected cell lines were cultured in G418 and/or Puromycin for 2 weeks and individual clones 
stably expressing human MPG or Polß were selected. It was recently suggested that p14
ARF
 
deficiency results in proteosome-mediated degradation of Polß (108). Although LN428 cells are 
deficient in p14
ARF
 (107), we note that the expression levels of Polß are stable. Transduction of 
LN428 cells with control lentivirus (GFP expression only) or human Polß or PARG specific 
shRNA lentivirus was completed as follows: Briefly, 6.0 x 10
4
 cells were seeded into 6-well 
plates and incubated for 24-30 hours at 10% CO2 at 37°C. Cells were transduced for 18 hours 
with virus at 32°C and cultured for 72 hours at 37°C before isolation of the GFP-expressing 
population by fluorescence-activated cell sorting (FACS) using the University of Pittsburgh 
Cancer Institute Flow Cytometry Facility. Cells were then cultured to expand the population and 
analyzed for expression of the target gene by qRT-PCR and/or immunoblot. MGMT over-
expression LN428 cell lines were developed by plasmid transfection. Briefly, 1.5 x 10
5
 cells 
were seeded into 60mm dishes and incubated for 24-30 hours (5% CO2 and at 37°C). The human 
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MGMT expression plasmid (pIRES-Puro-hMGMT) was transfected using FuGene 6 
Transfection Reagent (Roche, Indianapolis, IN) according to the manufacturer‟s instructions. 
Stable cell lines were selected in puromycin (0.5 µg/ml) for 2 weeks, individual clones (stably 
expressing human MGMT) were expanded and 30 µg of nuclear extract was analyzed by 
immunoblot analysis for the expression of human MGMT protein. All the cell lines developed 
and used in this study are described in APPENDIX A. 
 
4.2.2 Quantitative RT-PCR analysis 
Expression of PARG and Polß mRNA was measured by quantitative RT-PCR using an Applied 
Biosystems StepOnePlus system. Briefly, 80,000 cells were lysed and reverse transcribed using 
the Applied Biosystems Taqman® Gene Expression Cells-to-CT™ Kit. Each sample was 
analyzed in triplicate and the results are averages of all three analyses. Analysis of mRNA 
expression was conducted as per the manufacturer instructions (∆∆CT method) using Applied 
Biosystems TaqMan® Gene Expression Assays (human Polß: Hs00160263_m1; human PARG: 
Hs00608254_m1) and normalized to the expression of human ß-actin (part #4333762T). 
 
4.2.3 Cell extract preparation and immunoblot 
Nuclear extracts were prepared and protein concentration was determined as we described 
previously (51). Briefly, cells were washed with cold PBS, pelleted, and lysed using 
NucBuster
TM
 Protein Extraction Kit (Novagen). Protein concentration was determined using Bio-
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Rad Protein Assay (Bio-Rad). Twenty microgram of protein was loaded on a pre-cast 4-20% 
NuPAGE Tris-Glycine gel (InVitrogen). For whole cell extracts used in PAR formation assays, 3 
 106 cells were seeded into a 100 mm cell culture dish 24 hours before drug treatment. Cells 
were either treated with TMZ only or pre-exposed to a PARP inhibitor (PJ34 or DR2313) 
followed by PARP inhibitor plus TMZ treatment. After treatment, cells were washed twice with 
cold PBS, collected and lysed with 400 µL of 2X  Laemmli buffer (2% SDS, 20% Glycerol, 62.5 
mM Tris-HCl pH6.8, 0.01% Bromophenol Blue). Samples were boiled for 8 min and extract 
from approximately 1.5  105 cells were loaded each lane of a 4-12% pre-cast NuPAGE Tris-
Glycine gel (InVitrogen) for immunoblot analysis. 
The following primary antibodies were used in immunoblot analyses: anti-human MPG 
(Mab; clone 506-3D) (52); anti-Pol ß (Mab clone 61; Thermo Fisher Scientific); anti-APE1 
(EMD Biosciences); anti-PCNA (Santa Cruz); anti-Flag (M2 Mab; Sigma-Aldrich); anti-
poly(ADP-ribse) (PAR) (Clone 10H, kindly provided by M. Ziegler); anti-poly(ADP-ribose) 
polymerase-1 (PARP1) (BD Pharmingen) and anti-human HMGB1 (R&D Systems); anti-
MGMT (Novus, Littleton, CO). 
 
4.2.4 Cell cytotoxicity assay 
Short-term MTS cell survival assay: TMZ or TMZ + MX induced cytotoxicity was determined 
by an MTS assay, a modified MTT assay as described previously (51). For PJ34, DR2313, Z-
VAD.fmk, 3-MA, necrostatin-1, BAPTA-AM, and MX, cells were pre-exposed to the inhibitor 
for 30 minutes (PJ34, DR2313, necrostatin-1, BAPTA-AM, and MX) or one hour (Z-VAD.fmk 
and 3-MA) and were then treated with TMZ in the presence of the inhibitor for 48 hours. For NA 
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and NMN, cells were pre-exposed to each for 24 hours (concentrations as indicated in the 
legend) and were then treated with TMZ (1.0 mM) in the presence of NA or NMN for 48 hours. 
The impact on cell growth and survival was determined by an MTS assay, as described 
previously (51). Results were calculated from the average of three or four separate experiments 
and are reported as the percentage of treated cells relative to the cells without treatment (% 
Control).  
Long-term cell survival assay: Cells were seeded into 6-well plate with cell growth media 
without neomycin and/or puromycin 24 hours before exposure to PJ34 (4 μM), ABT-888 (10 
μM) or DMSO as control. 30 minutes later, cells were treated with TMZ alone, TMZ plus PJ34 
(2 μM) or TMZ plus ABT-888 (5 μM) for 6 hours. Cells were washed with PBS, trypsinized, 
resuspended and counted before being re-seeded into three 100 mm cell culture dishes at 8000 
cells (for LN428 cell lines) or 3000 cells (for T98G cell lines) each in cell growth media without 
neomycin and/or puromycin. Cells were incubated with or without 2 μM PJ34 or 5 μM ABT-888 
for 10 days and the cells were counted. Results were calculated from three independent 
experiments and reported as percentage relative to the control treatment (% Control). 
 
4.2.5 PAR assay 
Cells (1.5 x 10
6
) where seeded in 100mm dishes 24 hours before treatment. Media was then 
removed and replaced with fresh media or media supplemented with PJ34 (2 µM). After 30 
minutes, cells were lysed immediately (0 time point) or media was replaced with TMZ for the 
times indicated in the figure legends. Extracts were prepared by washing the cells with cold PBS 
and preparing cell extract with 400 µl of 2X Laemmli Buffer. 20 µl of the cell extract was 
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analyzed by immunoblot with a 4000-fold dilution of an anti-PAR primary antibody (Clone 10H) 
followed by a 5000-fold dilution of the horseradish peroxidase (HRP)-conjugated secondary goat 
anti-mouse Ab. 
 
4.2.6 HMGB1 release assay 
Cells were pre-treated with media alone or with PARP inhibitor (PJ34) for 30 min before co-
treatment with PJ34 (2 µM) and TMZ (1.5 mM) for 12 hours. Cell culture media was then 
collected and passed through 0.45 µM filters. 100 µL of immoblized Heparin (Thermo Fisher 
Scientific) slurry and 1 mL of media were mixed and rotated at 4°C for 2 hours before 
centrifugation at 8,000g to pull-down HMGB1 bound to immobilized Heparin (109). Pellets 
were boiled with 100 µL of 2X Laemmli buffer and supernatants were used for immunoblot 
analysis after brief centrifugation. 
4.2.7 Subcellular fractionation and analysis of AIF translocation 
Cells were seeded into 100 mm cell culture dishes at 3 × 10
6
 cells / dish. 24 hours later, cells 
were treated with TMZ (1.5 mM) for different periods of time before washing with cold PBS and 
subjecting to cell fractionation, essentially as described (110). Briefly, following treatment and 
washing, cells were collected by scraping using a rubber scraper. Cells were pelleted (400g, 5 
min at 4°C). The cell pellet was resuspended in 1 ml of cold homogenization buffer (0.25 M 
sucrose, 10 mM HEPES pH 7.4, 1 mM EGTA) and the cell suspension was homogenized in a 2 
ml Wheaton Dounce Homogenizer on ice. The homogenate was centrifuged at 1,000g for 15 
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minutes at 4°C to obtain the nuclear pellet, and the supernatant was then centrifuged at 10,000g 
for 15 minutes at 4°C to pellet mitochondria. 
 
4.2.8 Molecular beacon MPG activity assay 
Oligonucleotides used for the molecular beacon assay were purchased from Integrated DNA 
Technologies (Coralville, USA): FD-Con, 6-FAM-dGCACTATTGAATTGACACGCCATGTC 
GATCAATTCAATAGTGC-Dabcyl, where 6-FAM is carboxyfluorescein and Dabcyl is 4-(4‟-
dimethylaminophenylazo) benzoic acid; FD-MPG1, 6-FAM-dGCACTXTTGAATTGACACGC 
CATGTCGATCAATTCAATAGTGC-Dabcyl, where X is 1, N6-ethenoadenine (εA). 
These oligonucleotides were designed to form a stem-loop structure with 13 nucleotides situated 
in the loop and 15 base pairs in the stem. To ensure that the beacons correctly adapted their stem-
loop structure, they were heated at 95°C for 3 min and slowly cooled down to room temperature. 
Once the hairpin is formed, no measurable fluorescence was detected (not shown) and the 
hairpin is stable at 37°C for greater than 120 minutes. However, when heated to 95°C, the 
hairpin unfolds, resulting in maximum fluorescence intensity (not shown). Nuclear protein 
extracts were first prepared as described above then dialyzed twice in the following buffer for 90 
min: 50 mM Hepes pH7.5, 100 mM KCl, 0.5 mM EDTA, 20% Glycerol and 1 mM DTT. 
Reactions were performed using 2 μg of dialyzed protein extract and the FD-Con or FD-MPG1 
beacon (40 nM) in the following buffer: 25 mM HEPES-KOH pH7.8, 150 mM KCl, 0.5 mM 
EDTA, 1% Glycerol, 0.5 mM DTT. Fluorescence was measured using a StepOnePlus real-time 
PCR system and expressed as arbitrary units (AU). 
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5.0  RESULTS 
5.1 MECHANISM OF ALKYLATION SENSITIVITY MEDIATED BY INHIBITION 
OF BASE EXCISION REPAIR 
5.1.1 Base excision repair imbalance in human glioma cells increases cell sensitivity to 
alkylation damage 
BER is a finely tuned process that requires balanced expression of several proteins to avoid 
accumulation of mutagenic or cytotoxic repair intermediates (53). Further, multiple cellular 
factors control the response to the accumulation of base lesions or repair intermediates, resulting 
in varying outcomes when BER is inhibited or defective. For example, deficiency of the BER 
enzyme Mpg in the mouse provides resistance to alkylation-induced retinal degeneration and 
bone-marrow toxicity whereas -Mpg deficient mouse embryonic stem (ES) cells are sensitive to 
alkylation damage (111-113). Deficiency or inhibition of PARP1, another critical BER enzyme, 
has diverse outcomes, providing resistance to ischemia and stroke-induced neuronal cell death 
(114, 115) but sensitization to chemotherapy (45, 46). To understand how alterations in BER 
enzyme activity in human tumor cells leads to DNA damage-induced cell sensitivity, I developed 
human glioma (LN428) cell lines with a functional deficiency in Polß by increasing expression 
of MPG and depleting the cell of Polß by stable expression of shRNA (Figure 2.1A).  
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Figure 2.1 
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Figure 2.1 Alkylation sensitivity mediated by a deficiency in Pol ß-mediated DNA repair. 
(A) Characterization of glioma cell lines. Expression level of BER proteins including MPG, Polß 
and APE1 are shown for LN428 glioma cells (LN428), LN428 cells transduced by GFP 
expressing lentivirus (LN428/GFP), LN428 cells transfected with plasmid pIRES.neo.MPG to 
over-express MPG (LN428/MPG), MPG over-expressing glioma cells expressing GFP 
(LN428/MPG/GFP) or co-expressing GFP and Polß shRNA (LN428/MPG/Polß-KD). PCNA 
was used as a loading control.  
(B) Cell sensitivity to TMZ. Cells were cultured in 96-well plates for 24 hours prior to exposure 
to TMZ. After treatment (48 hrs), viable cells were determined using a modified MTT assay. 
Plots show the % viable cells as compared to untreated (control) cells. Means are calculated from 
quadruplicate values in each experiment. Results indicate the mean ± S.E. of three independent 
experiments. [LN428, open square; LN428/MPG, open circle; LN428/MPG/Polß-KD, open 
diamond] 
(C) Cell sensitivity to etoposide (ETO) exposure for 48 hours. Viable cells were measured as in 
(B). [LN428, open square; LN428/MPG, open circle; LN428/MPG/Polß-KD, open diamond] 
(D) (Upper panel) Cellular cytotoxicity due to TMZ treatment in LN428 cells over-expressing 
either WT or a glycosylase null mutant of MPG (N169D) following 48 hour exposure to TMZ. 
Viable cells were measured as in (B). [LN428, open square; LN428/MPG, open circle; 
LN428/MPG-mut, filled circle] (Lower panel) Western blots showing over-expression of mutant 
N169D-MPG (lane 2) as compared to LN428 cells transfected with the vehicle control (lane 1). 
(E) (Upper panel) Cellular cytotoxicity due to TMZ treatment in LN428/MPG/Polß-KD cells 
complemented with Flag tagged WT Polß (clone 2 and 6) following 48 hour exposure to TMZ. 
Viable cells were measured as in (B). [LN428, open square; LN428/MPG, o]en circle; 
LN428/MPG/Polß-KD, open diamond; LN428/MPG/Flag-Polß-WT, filled triangle; LN428/ 
MPG/Polß-KD /Flag-Polß-WT, filled triangle] (Lower panel) Over-expression of Flag tagged 
Polß (WT) in the LN428/MPG/Polß-KD cell line. An immunoblot from two representative 
clones (clone 2 and 6; lanes 4 and 5) are shown, compared to LN428/MPG cells (lane 1), 
LN428/MPG/Polß-KD cells (lane 2) and LN428/MPG/Polß-KD cells transfected with the 
vehicle control (lane 3). 
This figure is reproduced with permission from Supplemental Figure S1 of my recent publication 
in Mol Cancer Res (85).  
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As we have reported, human cells with elevated expression of MPG are sensitive to alkylation 
damage due to a deficiency in Polß (52). This DNA damage sensitive phenotype is enhanced by 
Polß knockdown (Polß-KD) (Figure 2.1A, B). This is in-line with a previous report by Dr. Sobol 
that Polß deficiency-induced sensitization of mouse fibroblasts to alkylating agents requires the 
expression of -Mpg (116). Cells were depleted of Polß by lentiviral-mediated expression of Polß 
specific shRNA, as we have described previously (52). Expression of Polß protein was not 
detectable by immunoblot (Figure 2.1A, lane 5) whereas Polß mRNA was reduced to 30% of 
the control, as determined by qRT-PCR (not shown).  
I find that over-expression of MPG alone and in combination with Polß knockdown 
(Figure 2.1A) sensitizes human glioma cells to DNA damage induced by the alkylating agents 
TMZ (Figure 2.1B), MMS and MNNG (Figure 2.8A) but not damage induced by a control 
DNA-damaging agent (an agent that causes DNA damage not repaired by BER), the 
topoisomerase II inhibitor etoposide (Figure 2.1C). Also as a control, I show that (i) this 
hypersensitive phenotype was not observed in cells expressing inactive MPG (Figure 2.1D) and 
(ii) over-expression of Polß eliminated the hypersensitive phenotype (Figure 2.1E), 
demonstrating that the increased alkylation sensitivity in the LN428/MPG and 
LN428/MPG/Polß-KD cells is due to a deficiency in Polß-mediated DNA repair. These cells are 
therefore functionally deficient in Polß and they were utilized to determine the mechanism that 
regulates the enhanced DNA damage-induced cell death resulting from Polß deficiency. 
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5.1.2 Hyperactivation of PARP due to Polß deficiency and failure to repair the BER 
intermediates 5’dRP 
The DNA binding and signaling molecules PARP1 and PARP2 have each been implicated in 
BER (53). PARP1 facilitates BER complex formation and it has been postulated that local, 
strand-break induced activation of PARP1 and the resultant synthesis of PAR mediates 
recruitment of the BER proteins XRCC1 and Polß to stimulate DNA repair (87). I therefore have 
hypothesized that in cells that fail to complete BER (e.g., when 5‟dRP lesions are not repaired; 
herein referred to as „BER Failure‟), PARP1 is hyper-activated and functions as a DNA damage 
signaling protein that triggers cell death. To determine whether PARP is activated by the BER  
intermediate (5‟dRP) in vivo, I exposed the control (LN428) and corresponding BER defective 
cells (Polß deficient LN428/MPG and LN428/MPG/Polß-KD cells) to TMZ for up to 90 
minutes. Whole cell extracts were probed by immunoblot for PAR accumulation following TMZ 
exposure (Figure 2.2A). The level of PAR accumulation was shown to correlate with the extent 
of the BER defect. PARP activation was elevated in the LN428/MPG cells (an intermediate level 
of sensitivity), with the highest level of PAR observed 30 minutes following exposure to TMZ 
whereas essentially no PARP activation was observed in the LN428 cells (Figure 2.2A). In the 
more sensitive cell line (LN428/MPG/Polß-KD), PARP activation was more robust and rapid as 
compared to that of the LN428/MPG cell line (Figure 2.2A), as PAR reached its highest level at 
15 minutes after exposure to TMZ. To ensure that these findings are not unique to this cell line, 
we characterized a second cell line in which Polß was depleted, the breast cancer cell line MDA-
MB-231. Comparable results were also observed in a Polß defective breast cancer cell line where 
elevated TMZ-induced PARP activation is restricted to the cells with Polß deficiency (85). 
Conversely, exposure to etoposide resulted in a low level of PARP activation at all time points  
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Figure 2.2 PARP activation due to BER failure 
(A) Immunoblot of PAR to determine activation of PARP after exposure to TMZ (1.5mM) for 
the time indicated. PARP1 and PCNA protein expression levels are also shown.  
(B) (Upper panel) TMZ induced cytotoxicity in LN428, LN428/MPG and two clones of 
Figure 2.2 
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LN428/MPG cells complemented with Flag-Polß-WT, measured as in Figure 2.1A. [LN428, 
open square; LN428/MPG, open circle; LN428/MPG/Flag-Polß-WT, clones 1 and 6, filled 
triangle] (Lower panel) Immunoblot of PAR to determine activation of PARP1 after exposure to 
TMZ (1.5mM) for the time indicated. PCNA is shown as a loading control. 
(C) (Upper panel) TMZ induced cytotoxicity in LN428, LN428/MPG and two clones of 
LN428/MPG cells complemented with Flag-Polß-K72A, measured as in Figure 2.1A. [LN428, 
open square; LN428/MPG, open circle; LN428/MPG/Flag-Polß-K72A, clones 5 and 16, filled 
triangle] (Lower panel) Immunoblot of PAR to determine activation of PARP1 after exposure to 
TMZ (1.5mM) for the time indicated. PCNA is shown as a loading control. 
This figure is reproduced with permission from Figure 1 of my recent publication in Mol Cancer 
Res (85). 
for all three cell lines LN428, LN428/MPG, and LN428/MPG/Polß-KD (Figure 2.8B). Thus, 
PARP activation is elevated in BER defective (Polß deficient) cells following alkylation damage. 
Since the combination of alkylating agent treatment and Polß deficiency triggers PARP 
activation, I next validated the significance and specificity of this finding by re-expression of  
Polß in the LN428/MPG and LN428/MPG/Polß-KD cells. I find that the BER deficient 
phenotype (increased cellular sensitivity to alkylating agents) observed in both the LN428/MPG 
and LN428/MPG/ Polß-KD cells was reversed by complementation (expression) of FLAG-Polß 
(WT) (Figure 2.1E & 2.2B, upper panel) but not the 5‟dRP lyase deficient (K72A) mutant of 
Polß (Figure 2.2C, upper panel). Similarly, I find that complementation with FLAG-Polß (WT) 
but not with the Polß 5‟dRP lyase mutant eliminated the TMZ-induced activation of PARP 
observed in BER defective cells (Figure 2.2B & C; lower panel). These data therefore suggests 
that the Polß specific BER intermediate (5‟dRP lesion) triggers rapid and robust PARP1 
activation in vivo, triggering the onset of cytotoxicity. 
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5.1.3 PARP activation is required for the alkylation sensitivity of Polß deficiency cells 
The correlation between PARP activation and alkylation sensitivity prompted us to determine if 
inhibition of PARP reverses the cellular hypersensitivity of Polß deficient human tumor cells. I 
inhibited activation of PARP by pre- and co-treatment with the PARP1/PARP2 inhibitors PJ34 
or DR2313. While the level of PARP activation in the control cells (LN428) in the presence or 
absence of the PARP inhibitor PJ34 or TMZ remains very low (Figure 2.3A; lanes 1, 2 & 5, 6), 
pre-treatment with PJ34 for 30 minutes followed by co-treatment with PJ34 and TMZ for an 
additional 30 minutes significantly reduced the level of PARP activation in the Polß deficient 
cells (LN428/MPG) (Figure 2.3A; lanes 3,4 & 7,8). I next assayed if PARP inhibition can rescue 
the alkylation-sensitive phenotype of LN428/MPG cells, as determined by an MTS assay 48 
hours after TMZ exposure. Most importantly, I find that PARP inhibition by either PJ34 or 
DR2313 treatment converted the LN428/MPG cells from a sensitive phenotype to a resistant 
phenotype (Figure 2.3B, C). Rescue by PARP inhibition was also observed in Polß deficient 
MDA-MB-231 cells (85). These studies support our hypothesis that PARP activation is required 
for the alkylation sensitive phenotype of Polß deficient cells.  
 
5.1.4 Base excision repair intermediates trigger cell death via energy depletion in the 
absence of PAR or PAR-catabolite mediated signaling 
The mechanism of cell death due to failure to repair the Polß substrate (a 5‟dRP containing DNA 
repair gap) is not known. I therefore systematically evaluated the involvement of caspase-
dependent, autophagy-dependent and caspase-independent cell death mechanisms in control cells  
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Figure 2.3 PARP activation mediates cellular hypersensitivity in BER defective cells 
(A) TMZ induced PARP activation in LN428 and LN428/MPG cells in the presence or absence 
of the PARP1/PARP2 inhibitor PJ34. Cells were pre-treated with PJ34 (4 µM) or vehicle control 
for 30 min before exposure to TMZ (1.5 mM) plus PJ34 (2 µM) for another 30 min. PCNA was 
used as a loading control.  
(B) TMZ induced cytotoxicity (LN428 and LN428/MPG cell lines) in the presence (solid lines) 
or absence (dashed lines) of the PARP1/PARP2 inhibitor PJ34. Viable cells were measured 48 
hours after exposure as in Figure 2.1B. [LN428, open and filled square; LN428/MPG, open and 
filled circle] 
(C) TMZ induced cytotoxicity (LN428 and LN428/MPG cell lines) in the presence (solid lines) 
or absence (dashed lines) of the PARP1/PARP2 inhibitor DR2313. Viable cells were measured 
48 hours after exposure as in Figure 2.1B. [LN428, open and filed square; LN428/MPG, open 
and filled circle] 
This figure is reproduced with permission from  Figure 2 and  Supplemental Figure S3.A of my 
recent publication in Mol Cancer Res (85). 
Figure 2.3 
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as compared to the corresponding Polß deficient cells following TMZ treatment. The increased 
sensitivity of the Polß deficient LN428/MPG cells, as compared to the control (LN428) cells was 
unaffected by the presence of the pan caspase inhibitor Z-VAD.fmk (Figure 2.4A). Whereas 
etoposide exposure of both the control and repair defective cells resulted in elevated caspase-3 
and -9 activation, little or no activation of caspase-3 or -9 was observed following 24 hours of 
TMZ exposure in all of the cell lines tested (85). Importantly, there is no difference in caspase 
activation when comparing the control cells (LN428) to the BER defective cells (LN428/MPG) 
(85). Both of these experiments therefore rule out a caspase-dependent response due to BER  
failure, in-line with our previous report (52). Although it has been demonstrated that an 
autophagic-response contributes to TMZ-induced cell death in some cells (117), TMZ 
hypersensitivity of Polß deficient cells is not affected by the autophagy inhibitor 3-MA (Figure 
2.4B). In support of this observation, we did not observe increased LC3 puncta in BER defective 
cells following TMZ exposure (52). Finally, one of the hallmarks of caspase-independent cell 
death is secretion of HMGB1 into the extracellular space (118, 119). A significant level of  
HMGB1 was secreted into the culture media following exposure of BER defective cells 
(LN428/MPG) to TMZ as compared to that of the control LN428 cells (Figure 2.4C). HMGB1 
release was mediated through PARP activation, likely due to PARP1 modification (119), as 
PARP inhibition greatly reduced the release of HMGB1 in BER defective cells (Figure 2.4C).  It 
is unclear how or if HMGB1 release due to failed BER is related to the recently reported role of 
HMGB1 in BER (120). In all, these data eliminate a role for either an autophagic or caspase-
dependent mechanism of cell death due to BER failure and together with the data presented 
above, provide support for a PARP1-activation induced mechanism of caspase-independent cell 
death upon alkylating-agent exposure of Polß deficient cells.  
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Figure 2.4 Alkylating agents induce PARP-dependent, caspase-independent cell death in 
Pol ß deficient LN428 cells. 
(A) TMZ-induced cytotoxicity in LN428 and LN428/MPG cells with or without pan caspase 
inhibitor Z-VAD.fmk (50 µM). Viable cells were measured 48 hours after exposure as in Figure 
2.1B. [LN428, open square; LN428 + Z-VAD.fmk, filled square; LN428/MPG, open circle; 
LN428/MPG + Z-VAD.fmk, filled circle] 
 (B) TMZ-induced cytotoxicity in LN428 and LN428/MPG cells with or without pre-treatment 
with the autophagy inhibitor 3-MA (4 mM). Viable cells were measured 48 hours after exposure 
as in Figure 2.1B. [LN428, open square; LN428 + 3-MA, filled square; LN428/MPG, open 
circle; LN428/MPG + 3-MA, filled circle] 
(C) HMGB1 released into the cell culture media, as demonstrated by immunoblot. LN428 and 
LN428/MPG cells were pre-treated with PJ34 (4 µM) or vehicle control for 30 min and then 
exposed to TMZ (1.5 mM) with or without PJ34 (2 µM) for 12 hours. HMGB1 was then 
captured using immobilized heparin and analyzed by immunoblot, as described in the 
Experimental Procedures section. 
This figure is reproduced with permission from Figure 3.D and Supplemental Figure S4.A & 
Figure S4.C of my recent publication in Mol Cancer Res (85). 
 
Figure 2.4 
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A number of different mechanisms have been attributed to PARP1-induced cell death. In 
one of these, cell death results from direct PAR signaling to the mitochondria where PAR 
mediates translocation of AIF from the mitochondria to the nucleus to induce caspase-
independent cell death (35, 64, 65) via a mechanism that requires RIP1 activation (121) (Figure 
2.5A). RIP1 is a serine-threonine kinase that functions as a key regulator of the cell death 
signaling pathways initiated by multiple insults (122). Further, RIP1 has been suggested to be 
involved in DNA damage-induced, p53-independent, caspase-independent cell death (123, 124). 
In addition, RIP1 controls PAR-mediated signaling to facilitate PARP1-induced AIF 
translocation from the mitochondria to the nucleus and the resulting cell death (121). RIP1 can 
be inhibited by necrostatins, small molecule inhibitors shown to inhibit cell death (125, 126). 
Therefore, I investigated the role of RIP1 in the PARP-mediated cell death by inhibiting RIP1 
with necrostatin-1 (126) and evaluating the impact of RIP1 inhibition on DNA damage-induced 
cell survival in both control and Polß deficient cells. However, inhibition of RIP1 did not prevent 
cell death in either the parental or Polß deficient cells (Figure 2.5B), suggesting but not proving 
that AIF translocation may not be related to the observed cell death.  
We therefore next evaluated the sub-cellular localization of AIF in control and Polß 
deficient cells following exposure to the alkylating agents MMS or TMZ as compared to vehicle 
(media) by sub-cellular fractionation and immunoblot analysis (Figure 2.5C) or by 
immunofluorescent staining and confocal microscopy (85). In-line with the RIP1 inhibition data 
above, alkylating agent treatment of Polß deficient cells did not alter the sub-cellular localization 
of AIF as shown by subcellular fractionation analysis (Figure 2.5C) and immunofluorescent 
microscopy evaluation (85). All the detectable AIF was localized to the mitochondria in both cell 
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Figure 2.5 Absence of PAR mediated cell death following BER failure 
(A) Model depicting the nexus of BER, the synthesis of PAR and the generation of PAR 
catabolites. 
(B) Inhibition of RIP1 by necrostatin-1 does not protect cells from TMZ-induced cytotoxicity. 
Cells were pre-treated with necrostatin-1 or vehicle control (DMSO) for 30 minutes and were 
then exposed to TMZ in the presence or absence of necrostatin-1 (100 M) for 48 hours. Viable 
cells were measured 48 hours after exposure as in Figure 2.1B. [LN428, open square; LN428 + 
necrostatin-1, filled square; LN428/MPG, open circle; LN428/MPG + necrostatin-1, filled circle] 
(C) Absence of mitochondria to nucleus translocation of AIF due to BER failure as determined 
by subcellular fractionation and immunoblot analysis. Cells were treated with 1.5 mM TMZ for 
the times indicated in the figure and subjected to subcellular fractionation and immunoblot 
analysis. COX IV and PCNA were used as controls to show no cross contamination between 
mitochondrial and nuclear fractions. COX IV and PCNA were also used as loading controls to 
show that equal amount of mitochondrial or nuclear samples were loaded. 
This figure is reproduced with permission from Figure 3.A and Supplemental Figure S5 & S6 of 
my recent publication in Mol Cancer Res (85). 
Figure 2.5  
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 lines regardless of agent or time of exposure (up to 12 hours), thus ruling out PAR as a cell 
death signal upon BER failure. 
In the absence of a PAR-mediated cell death process (AIF translocation), it is possible 
that cell death is initiated via the rapid breakdown of PAR (see Figure 2.2A) by the degradative 
enzyme PARG and the accumulation of the PAR catabolites ADP-ribose, ribose-5-phosphate 
and/or AMP (Figure 2.5A) (127). ADP-ribose acts as a second messenger to activate the cation 
channel TRPM2 to trigger Ca
2+
 influx, resulting in cell death (66, 67) or inhibit ABC 
transporters (128) whereas elevated AMP can block ATP transport, leading to ATP depletion and 
cell death (68). To investigate the possibility that PAR catabolites contribute to PARP-mediated 
cell death in Polß deficient cells, I first blocked Ca
2+
 influx with BAPTA-AM, shown recently by 
Boothman and colleagues to abrogate PARP1-activation induced cell death (129, 130). Unlike 
that observed following DNA damage from reactive oxygen species or oxidative stress, BAPTA-
AM did not prevent the elevated damage-induced cell death in Polß deficient cells (Figure 
2.6A). However, as there may be multiple mechanisms of PAR-catabolite-induced cell death, I 
next knocked-down expression of PARG by stable-transduction of both cell lines with a 
lentivirus expressing shRNA specific to PARG. Expression of PARG mRNA is reduced to 35% 
as compared to the GFP-control cells when determined by qRT-PCR (not shown). Importantly, I 
found no evidence for PAR degrading activity in the cells with stable depletion of PARG 
(Figure 2.6B). PARG knockdown cells (LN428/MPG/PARG-KD) do not accumulate 
spontaneous PAR (lane 1) yet when exposed to an alkylating agent, BER deficient PARG-KD 
cells accumulate significant levels of PAR with no evidence for PAR degradation (Figure 2.6B, 
lanes 2-4). This is in contrast to the presence of PARG, when the PAR molecule is degraded 
within 60-90 minutes (Figure 2.2, lanes 7-12). These data demonstrate that these PARG-KD  
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Figure 2.6 Absence of PAR-catabolite mediated cell death following BER failure 
(A) Inhibition of Ca2+ influx by BAPTA.AM does not protect cells from TMZ-induced 
cytotoxicity. Cells were pre-treated with BAPTA.AM or vehicle control (DMSO) for 30 minutes 
and were then exposed to TMZ in the presence or absence of BAPTA.AM (5 mM) for 48 hours. 
Viable cells were determined as in Figure 2.1B. Results were reported as the mean of three 
independent experiments ± S.E.M. [LN428, open square; LN428 + BAPTA.AM, filled square; 
LN428/MPG, open circle; LN428/MPG + BAPTA.AM, filled circle] 
(B) PARG KD prevented degradation of DNA damage-induced PAR. Immunoblot of PAR to 
determine the degradation of PAR in LN428/MPG cells following treatment with 1.5 mM TMZ. 
PCNA protein expression level was shown as a loading control. 
(C) Preventing generation of PAR catabolites from degradation of PAR via PARG KD does not 
protect cells from TMZ-induced cytotoxicity. LN428 and LN428/MPG cells with (black solid 
bars) or without (white empty bars) PARG KD were exposed to TMZ (1 mM) or vehicle control 
(DMSO) for 48 hours. Viable cells were determined as in Figure 2.1B and reported as 
percentage relative to vehicle control treated cells (% Control). Error bars represent S.E.M from 
three independent experiments. 
This figure is reproduced with permission from Figure 3.C and Supplemental Figure S7 of my 
recent publication in Mol Cancer Res (85). 
Figure 2.6 Figure 2.6 
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cells do not degrade PAR and hence do not accumulate PAR-catabolites, providing an 
opportunity to determine if PAR catabolites contribute to cell death in these cells. As shown in 
Figure 2.6C, PARG-KD did not rescue or reverse the enhanced damage-induced cell death 
phenotype of Polß deficient (LN428/MPG) cells. In fact, PARG-KD cells (black bars) were more 
sensitive to the cell killing effect of the alkylating agent TMZ as compared to the PARG 
expressing cells (open bars)(Figure 2.6C). The inability of necrostatins to abrogate the response  
and the lack of PAR-mediated AIF translocation strongly suggests that PAR is not acting as a 
signaling molecule to induce cell death, as has been suggested (131, 132). Further, the inability 
of BAPTA-AM and most importantly, PARG-KD, to reverse the alkylation-sensitive phenotype 
of Polß deficient cells also suggests that the observed cell death is un-related to the accumulation 
of PAR catabolites such as ADP-ribose or AMP (Figure 2.5A).  
An alternate process of cell death due to PARP1 activation was originally proposed by 
Berger to involve energy (NAD
+
 and ATP) depletion (133, 134), in support of an earlier 
observation by Jacobson and colleagues demonstrating a decrease in NAD
+
 concurrent with an  
increase in PAR synthesis (135). We therefore measured NAD
+
 and ATP levels in the control 
(LN428) and Polß deficient (LN428/MPG and LN428/MPG/Polß KD) cells before and after 
exposure to MMS or TMZ. In line with the cytotoxicity and PARP1 activation results described 
above, exposure of Polß deficient cells to MMS or TMZ led to a rapid and drastic depletion of 
both NAD
+
 and ATP whereas the NAD
+
 and ATP levels in the control cells were not affected 
(85). We next measured the impact of alkylation damage on the corresponding cells depleted of 
PARG (PARG-KD). If PAR catabolites trigger cell death, we would expect that NAD
+
 and ATP 
loss would be attenuated in PARG-KD cells. However, exposure of Polß deficient PARG-KD 
cells to TMZ led to enhanced depletion of both NAD
+
 and ATP (85). The absence of PAR or  
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Figure 2.7 BER failure induced cell death depends on NAD+ availability 
Bioenergetic metabolites rescue Polß deficient cells from DNA damage-induced cell death. 
LN428 and LN428/MPG cells were pre-treated with NMN, NA or vehicle control (media) for 24 
hours and were then exposed to TMZ (1 mM) in the presence or absence of NMN or NA for 48 
hours. Viable cells were measured as in Figure 2.1B. Results were reported as percentage 
relative to vehicle control treated cells (% Control) from three independent experiments ± S.E.M. 
This figure is reproduced with permission from Figure 4.C of my recent publication in Mol 
Cancer Res (85). 
PAR-catabolite mediated cell death together with the specific loss of NAD
+
 and ATP even when 
the formation of PAR-catabolites are prevented (85), suggests that the BER failure response is 
linked to the cellular bioenergetic capacity of the cell. 
For this paradigm to hold, I hypothesized that the availability of bioenergetic metabolites 
would impact the survival of Polß deficient cells exposed to an alkylating agent. In-line with this 
hypothesis, I find that supplementation of the cells with either NMN (136) or NA reversed the 
DNA damage-induced phenotype, rendering the Polß deficient cells (black bars) completely 
(NMN) or 90% (NA) resistant to the cell killing effects of the alkylating agent, as compared to  
Figure 2.7 
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Figure 2.8 Glioma cell response to MMS, MNNG and etoposide 
(A) Hypersensitivity of Polß deficient cells to TMZ, MMS and MNNG. Control cells (LN428, 
open bars) were resistant to alkylating agents, while the Polß deficient cells (LN428/MPG, black 
bars) were significantly more sensitive. Cells were exposed to 1500μM TMZ, 1500μM MMS or 
5μM MNNG for 48 hrs. Cell survival was determined by an MTS assay, while percent survival 
was normalized to untreated control cells, as in Figure 2.1B. Results are reported as the mean 
from three independent experiments and error bars represent S.E.M. 
(B) Immunoblot of PAR to determine activation of PARP1 after exposure of LN428, 
LN428/MPG and LN428/MPG/Polß KD cells to 50μM etoposide (ETO) for the time indicated. 
This figure is reproduced with permission from Supplemental Figure 2A & D of my recent 
publication in Mol Cancer Res (85). 
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the BER proficient cells (open bars) (Figure 2.7). Conversely, we anticipated that the 
hypersensitive phenotype of Polß deficient cells would be exacerbated by a reduction in the 
cellular level of NAD
+
 and related bioenergetic metabolites. We therefore evaluated the impact 
of transient NAD
+
 depletion on the observed “BER Failure” response by pre-treating cells with 
FK-866, a highly specific non-competitive small molecule inhibitor of nicotinamide 
phosphoribosyltransferase (NAMPT), a critical enzyme in the NAD
+
 biosynthetic salvage 
pathway that catalyzes the synthesis of NMN (137). Most importantly, the sensitivity of control 
cells to alkylation damage was not altered by FK-866 treatment. However, the BER deficient 
cells are 9-fold more sensitive to MMS following a non-toxic (10 nM) treatment with FK-866, as 
compared to the untreated cells (85) even though PAR synthesis after the combined FK-866 + 
MMS treatment is attenuated (85). These results support our overall hypothesis that the BER 
failure phenotype of Polß deficient cells is mediated by BER intermediate (5‟dRP) induced 
PARP1 activation and induction of caspase-independent cell death that is uniquely dependent on 
the availability of bioenergetic metabolites such as NMN and NAD
+
. 
5.2 N-METHYLPURINE DNA GLYCOSYLASE ENHANCES BER INHIBITION-
INDUCED POTENTIATION OF GLIOMA CELLS TO TEMOZOLOMIDE 
5.2.1 MX-induced potentiation of TMZ is enhanced by over-expression of N-
methylpurine DNA glycosylase 
To test our hypothesis that increased repair initiation by MPG will further sensitize glioma cells 
exposed to BER inhibitors, I stably over-expressed WT MPG in the glioma cell line LN428. 
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Over-expression of MPG was confirmed at the protein and mRNA levels using both immunoblot 
(Figure 3.1A) and qRT-PCR analyses, respectively (Figure 3.1B), with an approximate 40-fold 
increase of mRNA.  
To confirm increased glycosylase activity in the MPG over-expressing cells 
(LN428/MPG), I developed a fluorescent MPG activity assay using a modified form of 
molecular beacons, similar to those previously reported for oxidative damage (138). These 
molecular beacon repair substrates are stem-loop structures formed by single-stranded DNA with 
a fluorophore (6-FAM) and a quencher (Dabcyl) on either end of the oligonucleotide. A 1,N
6
-
ethenoadenine (εA), a substrate of MPG, was positioned in the stem region of the beacon at base 
#5 from the 5‟end and is used to probe for MPG activity. The same beacon structure with a 
normal adenine was used as the control substrate. Following removal of the 1,N
6
-ethenoadenine 
lesion by MPG and subsequent DNA strand excision by APE1 5‟ to the AP site, at 37°C the 5-
base long oligonucleotide containing the fluorophore 6-FAM separates from the quencher 
containing oligonucleotide and fluorescence signal can be detected at a wavelength of 517 nm as 
a measure of MPG activity (Figure 3.1C). Results of these experiments showed that the 
LN428/MPG cell line (Figure 3.1D, filled circle) had higher MPG activity as compared to the  
LN428 cell line (Figure 3.1D, filled rectangle). Cell extracts from both cell lines showed no 
activity when tested with the control substrate (Figure 3.1D, empty symbols), excluding the 
possibility that 6-FAM fluorescence signal results from non-specific cleavage of the molecular 
beacon. 
Using a short-term cell survival assay (48-hour MTS assay), I next assayed the 
potentiation of TMZ by MX in the LN428 cells with or without MPG over-expression. MX 
sensitized both cell lines to TMZ. In the LN428 cells, MX induced a 1.5-fold increase in  
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Figure 3.1 Over-expression of MPG in LN428 cells dramatically increases MX-induced 
potentiation of TMZ. 
(A) MPG over-expression as determined by immunoblot analysis of nuclear proteins isolated 
from the LN428 or LN428/MPG cells. Expression levels of the BER proteins Polß and APE1 are 
also shown here. PCNA expression is shown as a loading control.  
(B) MPG over-expression as determined by qRT-PCR analysis of RNA isolated from LN428 and 
LN428/MPG cells.  
(C) A schematic diagram showing the mechanism of the molecular beacon assay that is used in 
measuring the glycosylase activity of MPG. 
(D) Increased glycosylase activity in MPG over-expressing LN428/MPG cells as determined by 
the molecular beacon glycosylase activity assay. Results are reported as the mean fluorescence 
response unit of three independent experiment ± S.E.M.  
(E) MPG over-expression increases MX-induced potentiation of TMZ in LN428 cells. LN428 
cells (white triangle) or LN428/MPG cells (inverted white triangle) were cultured in 96-well 
plates for 24 hours prior to exposure to MX (filled symbols). Following exposure to MX (60 
mM) for 30 minutes, cells were treated with TMZ together with MX (30 mM) for 48 hours. 
Viable cells were determined using a modified MTT assay. Plots show the % viable cells as 
compared to untreated (control) cells. Means are calculated from quadruplicate values in each 
experiment. Results indicate the mean ± S.E.M. of three independent experiments.  
(F) Over-expression of the glycosylase inactive MPG mutant (N169D) in LN428 cells does not 
increase MX-induced potentiation of TMZ. 24 hours after seeding into 96-well plates, LN428 
cells over-expressing mutant MPG (N169D) were treated with (triangle) or without (open circle) 
MX (60 mM) for 30 minutes. Following MX pre-treatment, cells were exposed to TMZ in the 
presence (triangle) or absence (open circle) of MX (30 mM) for an additional 48 hours. Viable 
cells were counted and results were reported as in Figure 3.1E. 
sensitivity to TMZ (IC50, TMZ treatment: 1.5 mM; TMZ + MX treatment: 1.0 mM). However, 
the potentiation of TMZ induced by MX was 2 times higher in the LN428/MPG cells than in the 
LN428 cells as the IC50 was 0.8 mM and 0.25 mM for TMZ treatment or TMZ + MX treatment, 
respectively (Figure 3.1E & Figure 3.5). To confirm that MPG over-expression-induced 
potentiation is a result of elevated glycosylase activity, I over-expressed a mutant MPG (N169D), 
which has been shown to have 100-fold less glycosylase activity than the WT MPG (139), in the 
glioma cell line LN428 (85). Over-expression of the mutant MPG did not sensitize LN428 cells 
to a combined treatment of MX and TMZ (Figure 3.1F), which supports our hypothesis that 
MPG over-expression-induced sensitization is due to increased glycosylase activity in the cells.  
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5.2.2 MX-induced potentiation of TMZ is regulated by the expression of Polß 
Although MX reacts efficiently with AP sites in vitro (86), it is also possible that a proportion of 
the AP sites produced in cells following TMZ exposure will be processed by APE1 and 
subsequent steps of BER in vivo. To investigate the impact of AP site processing by BER 
proteins on MX-induced potentiation of TMZ, I over-expressed Polß, the rate-limiting enzyme of 
the BER pathway (140), and assayed MX-induced potentiation. Over-expression of WT Polß in 
the LN428/MPG cells (Figure 3.2A) completely abrogated the potentiation induced by MX 
(Figure 3.2B, compare to Figure 3.1E). In contrast, over-expression of a 5‟dRP lyase null mutant 
(K72A) (141, 142) of Polß (Figure 3.2B) did not affect MX-induced potentiation of TMZ 
(Figure 3.2C). Further, to determine whether increased expression of APE1 affects MX-induced 
potentiation of TMZ, I over-expressed APE1 in the LN428/MPG cells (Figure 3.2D and Figure 
3.6B). Interestingly, increased expression of APE1 did not alter the potentiation of TMZ induced 
by MX (Figure 3.2E). A possible explanation for this observation is that although over-
expression of APE1 increased its mRNA level by 20-fold, its protein level has only been slightly 
increased, which might not be able to significantly increase the number of AP sites processed by 
APE1 (see Figure 3.2D and Figure 3.6B). 
5.2.3 PARG deficiency-induced potentiation of TMZ is enhanced by over-expression of 
MPG in the presence of MGMT 
Next, I addressed chemotherapy sensitization in an MGMT positive background. The LN428 cell 
line used in our study has no detectable expression of MGMT (Figure 3.3A) as a result of 
epigenetic silencing by promoter methylation (Figure 3.6A). To study BER inhibition-induced  
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Figure 3.2 Over-expression of the BER protein Polß but not APE1 reverses MX-induced 
potentiation of TMZ in LN428/MPG cells. 
(A) Over-expression of WT Polß or the lyase activity null mutant (K72A) of Polß in 
LN428/MPG cells as determined by immunoblot analysis of nuclear protein extracted from 
LN428/MPG/VC (vector control, lane 1), LN428/MPG/Flag-Polß-WT (clone 1 and 6 expressing 
Flag-tagged WT Polß, lane 4 &5), and LN428/MPG/Flag-Polß-K72A (clone 5 and 16 expressing 
Flag-tagged mutant Polß, lane 2 &3) cells. PCNA is shown as a loading control.  
(B) Over-expression of Polß reverses MX-induced potentiation of TMZ in LN428/MPG cells. 
Cell viability assays were performed and results were reported as in Figure 3.1E. 
LN428/MPG/Flag-Polß-WT clone 1 (triangle), LN428/MPG/Flag-Polß-WT clone 6 (inverted 
triangle), cells treated with TMZ only (open symbols), cells treated with TMZ and MX (filled 
symbols). Dotted line with diamond symbols shows LN428/MPG cells treated with MX and 
TMZ as shown in Figure 3.1E.  
(C) Over-expression of mutant Polß (K72A) does not reverse MX-induced potentiation of TMZ 
in LN428/MPG cells. Cell viability assays were performed and results were reported as in Figure 
3.1E. LN428/MPG/Flag-Polß-K72A C5 (triangle), LN428/MPG/Flag-Polß-K72A C16 (inverted 
triangle), cells treated with TMZ only (open symbols), cells treated with TMZ and MX (filled 
symbols). Dotted line with diamond symbols shows LN428/MPG cells treated with MX and 
TMZ as shown in Figure 3.1E.  
(D) Immunoblot shows over-expression of Flag tagged APE1 in the LN428/MPG cells. Lane 1: 
LN428/MPG/vector control; lane 2: LN428/MPG/Flag-APE1 clone 4; lane 3: LN428/MPG/Flag-
APE1 clone 8. PCNA was used as a loading control.  
(E) Over-expression of APE1 does not reverse MX-induced potentiation of TMZ in 
LN428/MPG cells. Cell viability assays were performed and results were reported as in Figure 
3.1E. LN428/MPG/Flag-APE1 C4 (triangle), LN428/MPG/Flag-APE1 C8 (inverted triangle), 
cells treated with TMZ only (open symbols), cells treated with TMZ and MX (filled symbols). 
chemotherapy potentiation in the presence of MGMT expression, the LN428 and LN428/MPG 
cells were transfected with a mammalian expression plasmid (pIRES.Puro.hMGMT) and cell 
clones stably expressing MGMT were selected for further analysis (Figure 3.3B). Over-
expression of MGMT yielded LN428 cells resistance to TMZ in a long-term cell survival assay 
(Figure 3.3C).  
Although poly(ADP-ribosyl)ation of PARP1 and other BER proteins facilitates the repair 
of base lesions, the dynamics between PAR synthesis and  degradation is also important for the 
effectiveness of the repair process (82). Previously, it has been reported that a deficiency in the 
degradation of PAR negatively affects the repair of base lesions and sensitized cells to base  
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Figure 3.3 Over-expression of MPG increases PARG-KD-induced potentiation of TMZ in 
LN428/MGMT cells.  
(A) MGMT expression as determined by immunoblot analysis of nuclear protein isolated from 
LN428 cells (lane 1) and T98G cells (lane 2; used as a positive control). PCNA expression is 
shown as a loading control. (Thanks to Dr. Ram Trivedi for performing the immunoblot 
analysis.) 
(B) MGMT over-expression as determined by immunoblot analysis of nuclear proteins isolated 
from LN428 cells over-expressing MGMT (lane 1) and T98G cells (lane 2; used as a positive 
control). PCNA expression is shown as a loading control. (Thanks to Dr. Ram Trivedi for 
making the MGMT over-expression LN428 cell lines and performing the immunoblot analysis.) 
(C) Over-expression of MGMT provided the sensitive LN428 cells resistance to TMZ. Cell 
viability assays were performed and results were reported as in Figure 3.1E. LN428, empty 
circle; LN428/MGMT, empty rectangle.  
(D) A schematic diagram shows the five PARG shRNA constructs targeting PARG mRNA.  
(E) Decreased PARG mRNA expression levels induced by the five shRNA constructs targeting 
PARG. Results are reported as the mean ± SE of three independent qRT-PCR experiments.  
(F) PARG-KD induces delayed degradation of PAR in LN428/MPG cells following exposure to 
1.5 mM TMZ as demonstrated by immunoblot analysis.  
(G) PARG-KD (PARG-KD, black columns; control, white columns) significantly reduced cell 
survival following exposure to 300 μM TMZ in cells over expressing MPG 
(LN428/MGMT/MPG) as determined by long-term cell survival assay and sensitization was not 
statistically significant (ns) in LN428/MGMT cells with a low level of MPG expression.  
damage (88). Since PARG is the primary enzyme responsible for degrading PAR in vivo, in this 
study, I investigated whether depletion of PARG-induced potentiation of TMZ can be enhanced 
by over-expression of MPG. I first screened five different shRNA constructs targeting PARG 
(Figure 3.3D and APPENDIX B) using a HIV-lentiviral system (104, 105) in the LN428/MPG 
cells for effective depletion of the enzyme. Using RNA prepared from LN428/MPG cells 
expressing each of the five PARG-specific shRNAs, qRT-PCR results showed that the cells 
expressing shRNA#1 and shRNA#4 have the lowest levels of PARG mRNA (Figure 3.3E). To 
assay the impact of PARG shRNA expression on the ability of cells to degrade DNA damage-
induced PAR formation, control cells and cells treated with 1.5 mM TMZ were lysed at different 
time points and the lysates were probed for PAR in immunoblot analyses. Consistent with the 
qRT-PCR results, expression of PARG shRNA #1 and #4 greatly decreased the degradation of  
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Figure 3.4 Over-expression of MPG increases PAPR inhibitor-induced potentiation of 
TMZ in glioma cells expressing MGMT.  
(A) PJ34 significantly sensitized the MPG over-expression cells (LN428/MGMT/MPG), but not 
the LN428/MGMT cells to TMZ as measured by long-term cell survival assays. Triangle, 
LN428/MGMT cells; reversed triangle, LN428/MGMT/MPG cells; empty symbols, TMZ 
treatment only; filled symbols, PJ34 and TMZ treatment. Results were calculated as percentage 
survival relative to non-TMZ treated control cells (% Control) and reported as the mean ± S.E.M. 
of three independent experiments (*, p < 0.01, student t test).  
(B) Over-expression of MPG in T98G cells as shown by Immunoblot. T98G, lane 1; 
T98G/MPG, lane 2. Tubulin was used as a loading control.  
(C) Over-expression of MPG mRNA in T98G cells as shown by qRT-PCR.  
(D) Over-expression of MPG in T98G cells significantly increased ABT-888-induced 
potentiation of TMZ as measured by long-term cell survival assays. White bars, no TMZ 
Figure 3.4 
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treatment controls; lined bars, 50 μM TMZ treatment; black bars, 100 μM TMZ treatment. 
Results were calculated and reported as in Figure 3.4A. Statistics, student-t test, *: p < 0.05; **: 
p < 0.01. 
 
 
 
 
Figure 3.5 MPG over-expression increases MX-
induced potentiation of TMZ. 
LN428 cells (white triangle) or LN428/MPG cells 
(inverted white triangle) were cultured in 96-well 
plates for 24 hours prior to exposure to MX (filled 
symbols). Following exposure to MX (60 mM) for 30 
minutes, cells were treated with TMZ together with 
MX (30 mM) for 48 hours. Viable cells were 
determined using a modified MTT assay. Plots show 
the % viable cells as compared to untreated (control) 
cells. Means are calculated from quadruplicate values 
in each experiment. Results indicate the mean ± 
S.E.M. of three independent experiments.   
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PAR following exposure to TMZ (Figure 3.3F). Based on these results, I decided to use shRNA 
#4 for effective PARG KD in the following experiments. Further, to target tumor cells that 
express MGMT, I assayed PARG KD-induced potentiation of TMZ in the LN428 cell lines with 
over-expressed MGMT. First, I generated stable PARG KD in the MGMT expressing LN428 
and LN428/MPG cell lines as determined by qRT-PCR using the PARG shRNA #4 lentivirus 
(Figure 3.6C, D). Next, using long-term cell survival assays, I probed PARG KD-induced 
potentiation of TMZ in these cell lines. The results demonstrated that a deficiency in degrading 
PAR as a result of PARG KD significantly (p < 0.005) sensitized cells to TMZ (300 µM) in the 
MPG over-expressing cells (LN428/MGMT/MPG) by decreasing % cell viability from 87% to 
47% (Figure 3.3G), while sensitization by PARG KD was not statistically significant (p > 0.1) 
in the parental cells that exhibit a low (almost undetectable) level of MPG expression 
(LN428/MGMT) (Figure 3.3G). 
5.2.4 PARP inhibitor-induced potentiation of TMZ is enhanced by over-expression of 
MPG in the presence of MGMT 
Using a long-term cell survival assay, I next assessed if PARP inhibitor-induced potentiation of 
TMZ is affected by over-expression of MPG. I have previously shown that the PARP inhibitor 
PJ34 (2 μM) significantly reduced the level of PARP activation following exposure to TMZ (85). 
Here I show that pre- (4 μM) and co-treatment with PJ34 (2 μM) significantly sensitized cells to 
TMZ, with p < 0.01 for TMZ doses higher than 150 μM, and sensitization by PJ34 was not 
observed in the parental cells with a low level of MPG expression (LN428/MGMT) (Figure 
3.4A). To further confirm that over-expression of MPG increases PARP inhibition-induced 
potentiation of TMZ in glioma cells, I used a second glioma cell line T98G (143), which has  
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Figure 3.6 Cell line characterization 
(A) MGMT promoter methylation analysis of Bisulfite-treated DNA used for PCR in the DNA 
extracted from LN428 cells (Group 2, U: unmethylated and M: methylated), T98G cells (Group 
3, U: unmethylated and M: methylated), Universal unmethylated DNA as a negative control 
DNA (Group 1, U: unmethylated) and Universal methylated DNA as a positive control (Group 1, 
M: methylated). (The assay was performed by Xiao-hong Wang, Dr. Robert Sobol‟s laboratory.) 
(B) Over-expression of APE1 in LN428/MPG cells as shown by qRT-PCR. Two clones were 
shown here, C4 and C8.  
(C & D) qRT-PCR results showing PARG KD in MGMT over expressing LN428/MGMT (C) 
and LN428/MPG/MGMT (D) cells. Results are reported as the mean ± SE of three independent 
experiments. 
endogenously elevated expression of MGMT (Figure 3.3A, B). I inhibited BER using the 
clinically utilized PARP inhibitor ABT-888 in similar experiments as those conducted in the 
LN428 cell lines. I first over-expressed MPG in the T98G cells using a mammalian expression 
Figure 3.6 
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plasmid (pRS1422). Over-expression of MPG in the T98G cells increased its mRNA level (10-
fold) and protein level as determined by immunoblot and qRT-PCR analysis (Figure 3.4B, C). 
Consistent with previous reports that demonstrate ABT-888 potentiates TMZ in diverse tumor 
models (98, 144), treatment with ABT-888 sensitized T98G cells to TMZ (Figure 3.4D). More 
importantly, over-expression of MPG significantly increased the potentiation induced by ABT-
888 (Figure 3.4D, p < 0.05 and p < 0.01). These results demonstrate that increased base repair 
initiation enhances PARP inhibitor-induced potentiation of TMZ, suggesting that combining an 
increase in repair initiation and BER inhibition is an effective way to improve chemotherapeutic 
efficacy and the expression level of MPG in tumors might be used as a biomarker to predict 
effectiveness of alkylator chemotherapy potentiation. 
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6.0  DISCUSSION 
6.1 PARP ACTIVATION DEPENDENT CELL DEATH IN RESPONSE TO DNA 
BASE DAMAGE 
The requirement for BER in general and Polß more specifically in the repair of genomic DNA 
base damage, particularly DNA damage induced by alkylating agents such as the 
chemotherapeutic TMZ and the SN1 & SN2 alkylating agents MNNG and MMS, respectively 
(51, 57), elevates the significance of characterizing the mechanism responsible for Polß 
deficiency-induced cell death [e.g., a failure to complete repair of the BER intermediate 5‟dRP in 
the absence of Polß]. As evidenced recently by the development of clinically significant PARP 
inhibitors, identifying BER proteins critical for response to DNA damaging agents (e.g., 
chemotherapy) can have broad human health implications. Equally important is a clear 
understanding of the mechanism(s) that contribute to the enhanced cell death observed upon 
DNA repair inhibition. For example, PARP inhibition triggers apoptosis via the accumulation of 
DSBs (59, 60) and a requirement for HR proteins such as BRCA1 and BRCA2 (45). To this end, 
I have developed a unique series of genetically modified human tumor cell lines as models of 
Polß deficiency that accumulate the cytotoxic BER intermediate 5‟dRP following exposure to 
alkylating agents (TMZ, MMS and MNNG). By directly comparing the cellular, biochemical and 
signaling responses to DNA base damage in BER defective (Polß deficient) and BER competent 
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isogenic human cell lines, these responses can be defined as either global (non-specific) or BER 
(Polß) specific effects, the latter resulting from a cellular response to the inability to complete 
BER, referred to herein as “BER Failure”. I have then utilized this system to define the 
mechanism of cell death resulting from Polß loss/inhibition or BER failure and propose and test 
paradigms to enhance the cell death response.  
From these studies, I find that the un-repaired BER intermediates that accumulate upon 
DNA damaging agent exposure when Polß is deficient will activate PARP1, leading to a rapid 
onset of PARP1-dependent, caspase-independent cell death with little or no role for a caspase-
dependent or autophagy-dependent process in the response. It remains to be determined if the 
BER failure-induced cell death observed herein is dependent on ERK1/2–mediated PARP1 
phosphorylation (145), SIRT1-regulated deacetylation of PARP1 (146) or if the observed 
PARP1-induced cell death requires BAX, Calpain and JNK activation (147). Coincident with 
damage-induced necrosis in Polß deficient cells is PARP1-dependent HMGB1 secretion (119), a 
hallmark of caspase-independent cell death and inflammation signaling. HMGB1 functions in the 
extra-cellular space as a robust RAGE ligand and inflammatory cytokine or damage-associated 
molecular pattern molecule (118), suggesting that BER failure and the resulting PARP1 
activation may trigger an inflammatory response in tissues with a BER imbalance such as 
ulcerative colitis (148). 
There are multiple PARP1-activation induced cell death mechanisms, as outlined in the 
diagram shown in Figure 2.5A. In one, it is suggested that PAR, the product of PARP1 
activation, is a cell death molecule. In this process, PAR initiates the translocation of AIF from 
the mitochondria to the nucleus by a RIP1-dependent mechanism (35, 64, 65, 121) (Figure 
2.5A). Uniquely, PAR generated due to BER failure does not appear to trigger cell death via 
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RIP1 activation nor does PAR function as a signal to initiate AIF translocation. PARP1 is 
involved in many DNA repair processes including homologous recombination (HR) and non-
homologous end joining (NHEJ) in response to DSBs and has a role in telomere maintenance 
(32, 33). The question remains if PAR generated via BER failure is of a unique chemical make-
up as compared to PAR generated from DSB-induced PARP1 activation. One possible 
explanation for the absence of a role for AIF in this study is the concentration of DNA damaging 
agents used. In this report, we have used TMZ or MMS at a maximum concentration of 1.5 mM 
or MNNG at a concentration of 5 µM, resulting in 90-95% cell death in the BER deficient cells 
with little or no cell death in the control cells (Figure 2.8A). Many reports of PAR-induced AIF 
translocation include MNNG concentrations of 100 and 500 µM (147, 149, 150). Such high 
concentrations of DNA damaging gents (e.g., MNNG at 20X and 100X that used herein) have 
the potential to directly induce DNA DSBs, create overwhelming levels of both nuclear and 
mitochondrial genome damage (151) as well as the possibility of direct protein alkylation. 
Regardless, it is clear that the cell death initiated by BER failure is independent of RIP1 
activation and AIF translocation, thus ruling out PAR as the cell death signal that is initiated 
upon BER failure. 
One explanation for the absence of PAR-mediated cell death is the rapid catabolism of 
PAR by PARG (127). In this study, I find that PAR synthesized due to PARP activation is 
degraded within 90 minutes (Figure 2.2). As summarized in Figure 2.5A, the breakdown 
products of PAR (PAR catabolites) are also likely mediators of cell death, including ADP-ribose 
(activator of the Ca
2+
 channel TRPM2) and AMP (inhibitor of ATP transport) (66-68). However, 
PARG knockdown did not reverse the DNA damage-sensitive phenotype of Polß deficient cells 
(Figure 2.6C), suggesting that damage-dependent cell death in Polß deficient cells is not 
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initiated by PAR catabolites. Conversely, the PAR catabolite AMP may provide a protective 
phenotype by activation of AMPK, induction of autophagy and enhanced ATP synthesis, as 
recently reported following ROS-induced DNA damage and PARP1 activation (152). Although 
loss of AMPK activation and induction of autophagy upon PARG-KD could explain, in part, the 
enhanced cell death observed in the PARG-KD cells (Figure 2.6C), we suggest this is unlikely, 
since in this study, autophagy is not involved (Figure 2.4B) and the activation of AMPK, if any, 
does not appear to overcome the damage-induced cell death phenotype resulting from BER 
failure in the PARG proficient cells. Regardless, it is interesting to speculate that PARG may 
regulate AMPK activation in response to ROS-induced PARP1 activation (152). In all, these 
studies imply that the alkylation-sensitive phenotype of Polß deficient cells is un-related to the 
accumulation of PAR catabolites such as ADP-ribose or AMP and is likely wholly dependent on 
the metabolite bioavailability or bioenergetic capacity of the cell.  
 The over-riding response to the loss of Polß and an inability to complete BER (BER 
failure) is energy failure or depletion of bioenergetic metabolites with no evidence for cell death 
triggered by PAR or the PAR catabolites ADP-ribose or AMP. The energy collapse or depletion 
of NAD
+
 and ATP due to BER failure is offset by elevated levels of NMN (136) and is 
negatively affected by NAD
+
 biosynthesis inhibition (FK-866), suggesting that (i) FK-866 
(APO866) and related clinically useful NAD
+
 biosynthesis inhibitors might be combined with 
TMZ and BER inhibitors to improve TMZ response and (ii) any stress on or defects in the NAD
+
 
biosynthesis pathway such as over-activation of SIRT1 (153) or attenuating defects in NAMPT, 
NMNAT1 or related NAD biosynthetic enzymes (154) may have significant effects on cell 
survival following BER failure.  
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Similar phenotypes (stress-induced PARP1 activation and cell survival dependent on 
NAD
+
 metabolites) have been observed in diverse human cell types and mammalian organ 
systems, stressing the significance of these findings. PARP1 activation and the resulting “NAD+ 
depletion”-mediated or ATP-depletion mediated cell death plays a critical role in tissue injury 
from cerebral and myocardial ischemia (114, 115, 155, 156). Analogous to the studies described 
herein, cellular protection from cerebral ischemia is provided by NAD
+
 metabolite 
supplementation (157, 158). Similarly, streptozotocin-induced diabetes results from PARP1 
activation, energy imbalance and cell death dependent on the BER enzyme MPG (159-162). 
Most importantly, cellular NAD
+
 metabolism plays an essential role in pancreatic ß-cell viability 
and insulin secretion (163). With the observation that BER failure triggers NAD
+
 depletion, it is 
interesting to speculate if overall BER capacity controls susceptibility to ischemia or 
streptozotocin-induced and age-related diabetes onset via neuronal or ß-cell death from loss of 
bioenergetic metabolites subsequent to BER failure. The onset of these physiologically 
significant outcomes (stroke, neurodegeneration, ischemia, diabetes) involves PARP1 activation, 
NAD
+
 depletion and cell death, similar to that reported here. Although a portion of the 
environmental and endogenous stressors that induce these phenotypes via PARP1 activation will 
directly induce DNA single-strand breaks, it is reasonable to presume that a significant 
proportion of cell death related to stroke, retinal degeneration, ischemia and diabetes may initiate 
from genomic DNA base damage, requiring repair by the BER machinery. As such, the failure to 
repair the DNA damage and the resulting accumulation of DNA repair intermediates (BER 
failure) may be the trigger of PARP1 activation and cell death.  
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 In summary, these studies suggest that PARP1 functions as a BER molecular sensor 
protein to induce caspase-independent cell death following BER failure and provides 
mechanistic insight into why Polß deficiency leads to cell death. Further, these studies 
demonstrate that the observed DNA damage dependent cell death in Polß deficient cells is un-
related to the accumulation of PAR catabolites such as ADP-ribose or AMP yet is dependent on 
NAD
+
 metabolite bioavailability or bioenergetic capacity of the cell, suggesting a linkage 
between DNA repair capacity, cell survival and cellular bioenergetic metabolites. Finally, these 
studies have potentially important implications for therapeutic development as it relates to a 
chemotherapy-induced synthetic lethality approach to cancer therapy involving the combination 
of a chemotherapeutic DNA damaging agent, a DNA repair inhibitor and a regulator or inhibitor 
of NAD
+
 biosynthesis.  
6.2 EXPRESSION OF MPG DRIVES BER INHIBITION-INDUCED 
CHEMOTHERAPY SENSITIZATION 
As the first enzyme in the BER pathway for the repair of alkylated bases, glycosylase activity of 
MPG is required for the initiation of BER to repair a spectrum of lesions, including 3MeA and 
7MeG (76). It has been demonstrated that MPG expression levels vary considerably in human 
breast cancer (164), astrocytic tumors (165) and glioblastoma. In addition, MPG possesses 
multiple post translational modifications and interacts with many DNA repair proteins, including 
XRCC1 and hR23A, suggesting that the glycosylase activity of MPG may be under tight cellular 
regulation (53). Here, I demonstrate that BER inhibition-mediated sensitization of glioma cells to 
the chemotherapeutic agent TMZ is further increased by enhancing BER repair initiation via 
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over-expression of MPG. Glioma cells with elevated-expression of MPG exhibited dramatically 
increased potentiation of TMZ via BER inhibition by MX, the PARP inhibitors PJ34 and ABT-
888 or by PARG depletion (PARG-KD). The enhanced potentiation of TMZ in the MPG over-
expressing glioma cell lines observed in these studies is in-line with a previous report showing 
that MX-induced sensitization is increased by MPG over-expression in ovarian cancer cells (49). 
However, the expression level of MPG is not the only factor that controls MX-induced 
potentiation of TMZ, as it is also related to the efficiency and balance of the BER pathway 
proteins that process AP sites and downstream repair intermediates. From these experiments 
(Figure 3.2B & C), it is demonstrated that over-expression of the wild type BER rate-limiting 
enzyme Polß but not the 5‟dRP lyase activity null mutant of Polß (K72A), in the MPG over-
expressing cells, abrogates the MPG dependent potentiation of TMZ. Therefore, it is the 
collective expression status of both MPG and Polß that defines the sensitization induced by MX. 
APE1 is the main enzyme that directly competes with MX for the processing of AP sites in cells, 
yet over-expression of the enzyme did not alter MX-induced potentiation of TMZ (Figure 3.2E). 
A possible explanation might be that although APE1 mRNA level was increased by more than 
20X (Figure 3.6B) the protein level of APE1 was only slightly increased (Figure 3.2D). Since 
APE1 is an abundant enzyme in cells, a slight increase of the protein level of APE1 may not 
change the rate of AP sites processed by APE1 or MX. 
According to our previous study, the dynamics between PAR synthesis and degradation 
are not only involved in facilitating repair of base lesions, but also acts as a mediator of cell 
death via hyperactivation of PARP and subsequent cellular energy depletion in response to 
accumulation of un-repaired BER intermediates (85). Thus, although inhibition of PARP 
hyperactivation and PAR synthesis provides short-term cell survival advantage, it is very likely 
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that damage-induced DNA lesions persist in cells due to inhibition of PARP. Cells harboring the 
un-repaired DNA lesions will eventually die due to accumulation of DSBs as cells go through 
replication. Therefore, in the context of chemotherapy sensitization involving PARP inhibition or 
depletion of PARG (PARG KD), the long-term assay (10 days) for cell survival, which allows 
for multiple rounds of DNA replication, is more suitable than the short-term (2 days) MTS assay. 
For the reason stated above, all the cell survival assays involving PARG or PARP inhibition 
were conducted using the long-term assay as described in the Materials and Methods section.  
PARG is the primary enzyme for degrading PAR in human cells. It has been reported that 
the PARG inhibitor GPI 16552 chemosensitizes malignant melanoma to TMZ (82), which 
implies that not only poly(ADP-ribosyl)ation of target proteins by PARP but also the rapid 
clearance of PAR by PARG is important for cell survival following DNA base damage. 
Contradictory to the previous report demonstrating that PARG inhibition sensitizes melanoma to 
TMZ (82), these studies demonstrate that shRNA-mediated PARG-KD did not significantly (p > 
0.1) sensitize the LN428/MGMT cells to TMZ. However, I found that the sensitization is 
significant (p < 0.005) in cells with over-expression of MPG (Figure 3.3G). 
PARP has recently become the focus of investigations of chemotherapy potentiation 
since the publication of a sensitive phenotype induced by PARP inhibitors in breast cancer cells 
bearing a loss of BRCA1 or BRCA2 function (166, 167). Currently, PARP inhibitors are under 
phase 0 to phase 2 clinical trials in combination with the clinical alkylating agent TMZ (89). The 
rationale for combining a PARP inhibitor with TMZ is generally considered to be inhibition of 
repair of TMZ-induced DNA lesions via inhibiting PARP. However, it is not known if the status 
of the BER pathway inherent in cancer cells has an impact on the potentiation induced by PARP 
inhibitors. In this study, using the PARP inhibitors PJ34 and ABT-888, these studies demonstrate 
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that PARP inhibition-induced potentiation of TMZ is significantly enhanced in glioma cells with 
elevated expression of MPG (Figure 3.4A, D), suggesting that increased repair initiation of 
TMZ-induced base lesions can further sensitize cancer cells to PARP inhibition and that the 
expression level of MPG in cancer cells may predict clinical benefit of PARP inhibitors in 
combination with TMZ. 
 This study addresses the relationship between DNA glycosylase expression and 
chemotherapy sensitization via BER inhibition (MX, the PARP inhibitors PJ34 and ABT-888 or 
PARG-KD). These studies demonstrate that BER inhibition-induced potentiation of TMZ is 
enhanced by over-expression of the BER initiating enzyme MPG, suggesting that combining an 
increase in repair initiation and inhibition of repair following initiation of the BER pathway is an 
effective means to improved chemotherapy efficacy. Further these studies suggest that the 
expression level of MPG in cancer cells might be used to predict effectiveness when combining 
BER inhibition and alkylating agents. 
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APPENDIX A 
CELL LINES DEVELOPED AND USED IN 5.1 
Cell line name 
Clone 
# 
Cell line description Growth media 
LN428 - Human glioma cell line 
Alpha EMEM, heat-
inactivated fetal bovine 
serum (10%), glutamine 
(2 mM), antibiotic & 
antimycotic, gentamicin 
(50 µg/ml). 
LN428/Pol ß KD - 
LN428 cells expressing Polß 
shRNA and copGFP 
LN428 cell growth media 
LN428//MPG 7 
LN428 cells modified for 
over-expression of human 
MPG 
LN428 cell growth media 
+ 600 µg/ml neomycin 
LN428//MPG/ Pol ß KD - 
LN428 cells modified for 
over-expression of human 
MPG, expressing Polß 
shRNA and copGFP 
LN428 cell growth media 
+ 600 µg/ml neomycin 
LN428/MPG/GFP - 
LN428/MPG cells 
expressing copGFP 
LN428 cell growth media 
+ 600 µg/ml neomycin 
LN428/VC* 1 
LN428 cells transfected with 
vector control plasmid 
pIRES-neo 
LN428 cell growth media 
+ 600 µg/ml neomycin 
LN428/MPG/VC* 2 
LN428/MPG cells 
transfected with vector 
control plasmid pIRES-puro 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
LN428/MPG/Pol ß KD/VC* 3 
LN428/MPG/Polß-KD cells 
transfected with vector 
control plasmid pIRES-puro 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
LN428/MPG-N169D 11 
LN428 cells modified to 
express glycosylase dead 
LN428 cell growth media 
+ 600 µg/ml neomycin 
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mutant of MPG (N169D) 
LN428/MPG/Flag-Pol ß-
WT* 
1 LN428/MPG cells 
expressing Flag tagged WT 
Polß 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
6 
LN428/MPG/Flag-Pol ß-
K72A 
5 LN428/MPG cells 
expressing Flag tagged 
5‟dRP lyase activity dead 
mutant Polß 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
16 
LN428/MPG/Pol ß 
KD/Flag-Pol ß-WT* 
2 LN428/MPG/Pol ß KD cells 
expressing Flag tagged WT 
Polß 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
6 
LN428/MPG/Flag-APE1 
4 LN428/MPG cells over-
expressing Flag tagged 
APE1 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
8 
LN428/MGMT 5 
LN428 cells over-expressing 
human MGMT 
LN428 cell growth media 
+ 1.0 μg/ml puromycin 
LN428/MPG/MGMT 8 
LN428/MPG cells over-
expressing human MGMT 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
LN428/MGMT/PARG KD - 
LN428/MGMT cells co-
expressing PARG shRNA 
and TurboGFP 
LN428 cell growth media 
+ 1.0 μg/ml puromycin 
LN428/MPG/MGMT/PARG 
KD 
- 
LN428/MPG/MGMT cells 
co-expressing PARG shRNA 
and TurboGFP 
LN428 cell growth media 
+ 600 µg/ml neomycin + 
1.0 µg/ml puromycin 
T98G - Human glioma cell line 
EMEM, FBS (10%), 
sodium pyruvate, MEM 
non-essential amino 
acids, antibiotic & 
antimycotic, gentamycin 
T98G/MPG 1 
T98G cells over-expressing 
human MPG 
T98G cell growth media 
+ 400 µg/ml neomycin 
 
VC*: vector control. 
WT*: wild type. 
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APPENDIX B 
MISSION™ TRC SHRNA TARGET SET FOR PARG 
TRC No.  ShRNA # 
TRCN0000
051303 
CCGGGCTAAGATGAAATCGGAGTATCTCGAGATACTCCGATT
TCATCTTAGCTTTTTG 
Clone ID: NM_003631.1-2105s1c1  
Accession Number(s): NM_003631.2  
Region: CDS 
1 
TRCN0000
051306 
CCGGCGATTGCATGTCACTTACGAACTCGAGTTCGTAAGTGA
CATGCAATCGTTTTTG 
Clone ID: NM_003631.1-2315s1c1  
Accession Number(s): NM_003631.2  
Region: CDS 
2 
TRCN0000
051307 
CCGGGCCTAGGAAATTCTCCTCCATCTCGAGATGGAGGAGAA
TTTCCTAGGCTTTTTG 
Clone ID: NM_003631.1-1026s1c1  
Accession Number(s): NM_003631.2  
Region: CDS 
3 
TRCN0000
051305 
CCGGGCTGAGCGAGATGTGGTTTATCTCGAGATAAACCACAT
CTCGCTCAGCTTTTTG 
Clone ID: NM_003631.1-2843s1c1  
Accession Number(s): NM_003631.2, XM_937616.2  
Region: CDS 
4 
TRCN0000
051304 
CCGGGCAGTTTAGTAATGCTAACATCTCGAGATGTTAGCATTA
CTAAACTGCTTTTTG 
Clone ID: NM_003631.1-706s1c1  
Accession Number(s): NM_003631.2  
Region: CDS 
5 
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